<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-48700-8
   </article-id>
   <article-id pub-id-type="manuscript">
    48700
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-48700-8
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/67/1612/1350
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/67/1612/1350
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/67/580
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /38/91
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Single-cell and spatial transcriptomics analysis of non-small cell lung cancer
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-1230-2714
     </contrib-id>
     <name name-style="western">
      <surname>
       De Zuani
      </surname>
      <given-names>
       Marco
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-1264-5303
     </contrib-id>
     <name name-style="western">
      <surname>
       Xue
      </surname>
      <given-names>
       Haoliang
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-7149-6769
     </contrib-id>
     <name name-style="western">
      <surname>
       Park
      </surname>
      <given-names>
       Jun Sung
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Dentro
      </surname>
      <given-names>
       Stefan C.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-3131-3697
     </contrib-id>
     <name name-style="western">
      <surname>
       Seferbekova
      </surname>
      <given-names>
       Zaira
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Tessier
      </surname>
      <given-names>
       Julien
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Curras-Alonso
      </surname>
      <given-names>
       Sandra
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Hadjipanayis
      </surname>
      <given-names>
       Angela
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-2771-5562
     </contrib-id>
     <name name-style="western">
      <surname>
       Athanasiadis
      </surname>
      <given-names>
       Emmanouil I.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff9">
      9
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <name name-style="western">
      <surname>
       Gerstung
      </surname>
      <given-names>
       Moritz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-6055-277X
     </contrib-id>
     <name name-style="western">
      <surname>
       Bayraktar
      </surname>
      <given-names>
       Omer
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au12">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-3204-9311
     </contrib-id>
     <name name-style="western">
      <surname>
       Cvejic
      </surname>
      <given-names>
       Ana
      </given-names>
     </name>
     <address>
      <email>
       ana.cvejic@bric.ku.dk
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
     <xref ref-type="corresp" rid="IDs41467024487008_cor12">
      n
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05cy4wa09
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.10306.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0606 5382
      </institution-id>
      <institution content-type="org-division">
       Wellcome Sanger Institute
      </institution>
      <institution content-type="org-name">
       Wellcome Genome Campus
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hinxton
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.52788.30
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0427 7672
      </institution-id>
      <institution content-type="org-division">
       OpenTargets
      </institution>
      <institution content-type="org-name">
       Wellcome Genome Campus
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hinxton
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/013meh722
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5335.0
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2188 5934
      </institution-id>
      <institution content-type="org-division">
       Department of Haematology
      </institution>
      <institution content-type="org-name">
       University of Cambridge
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Cambridge
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.14105.31
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000000122478951
      </institution-id>
      <institution content-type="org-name">
       Wellcome Trust—Medical Research Council Cambridge Stem Cell Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Cambridge
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.52788.30
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0427 7672
      </institution-id>
      <institution content-type="org-division">
       European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI
      </institution>
      <institution content-type="org-name">
       Wellcome Genome Campus
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hinxton
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-division">
       Division of Artificial Intelligence in Oncology
      </institution>
      <institution content-type="org-name">
       DKFZ
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Heidelberg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.417555.7
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0000 8814 392X
      </institution-id>
      <institution content-type="org-division">
       Precision Medicine and Computational Biology
      </institution>
      <institution content-type="org-name">
       Sanofi
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Cambridge
     </addr-line>
     <addr-line content-type="state">
      MA
     </addr-line>
     <country country="US">
      USA
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/02n6c9837
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.417924.d
      </institution-id>
      <institution content-type="org-division">
       Precision Medicine and Computational Biology
      </institution>
      <institution content-type="org-name">
       Sanofi
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Paris
     </addr-line>
     <country country="FR">
      France
     </country>
    </aff>
    <aff id="Aff9">
     <label>
      9
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00r2r5k05
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.499377.7
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 7222 9074
      </institution-id>
      <institution content-type="org-division">
       Medical Image and Signal Processing Laboratory (MEDISP), Department of Biomedical Engineering
      </institution>
      <institution content-type="org-name">
       University of West Attica
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Athens
     </addr-line>
     <country country="GR">
      Greece
     </country>
    </aff>
    <aff id="Aff10">
     <label>
      10
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/035b05819
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5254.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 0674 042X
      </institution-id>
      <institution content-type="org-division">
       Biotech Research &amp; Innovation Centre (BRIC)
      </institution>
      <institution content-type="org-name">
       University of Copenhagen
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Copenhagen
     </addr-line>
     <country country="DK">
      Denmark
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Marco De Zuani, Haoliang Xue.
     </p>
    </fn>
    <corresp id="IDs41467024487008_cor12">
     <label>
      n
     </label>
     <email>
      ana.cvejic@bric.ku.dk
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     23
    </day>
    <month>
     5
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="4388">
    1
   </issue>
   <elocation-id>
    4388
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      13
     </day>
     <month>
      5
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      2
     </day>
     <month>
      11
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      8
     </day>
     <month>
      5
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      23
     </day>
     <month>
      5
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Abstract
    </title>
    <p id="Par1">
     Sita kifupi ni kasi ambacho linatambuliwa mara ya pili kwa mara kubwa na linahusisha ufarukaruku wa watu duniani kwa sababu ya maradhi. Mazingira ya tumori yana aina mbalimbali za nyuzi. Nyuzi ya myeloid, hasa, ni wanaotofautiana na yana athari kubwa ya kusaidia maradhi. Katika utafiti wetu, tulipata mikakati 900,000 kutoka kwa watu 25 ambao hawejatolewa dawa na wana tumori ya adenocarcinoma na squamous-cell carcinoma kwa kutumia teknolojia ya mikakati na transcriptomics ya maeneo. Tulipata uhusiano uliyokaribisha kati ya nyuzi za kurejelea usimamizi na nyuzi za NK na T, na pia kurejelea usimamizi wa nyuzi za NK ndani ya tumori. Ingawa tulipata uhusiano wa aina ya nyuzi kati ya adenocarcinoma na squamous-cell carcinoma, tulipata tofauti muhimu katika uhusiano wa kutoa kwa kila mara wa nyuzi za kurejelea usimamizi. Pia, tulipata uhusiano wa athari za "reprogramming" ya nyuzi za macrophages ndani ya tumori, yanayohakikisha wanaenda kwa usimamizi wa cholesterol na kuzingatia athari za kurejelea usimamizi kama ambavyo yanayofaa kwa kurejelea usimamizi wa madini. Rasilimali zetu za multi-omic zinaelezea ramani ya molecular ya kifupi ya nyuzi za macrophages yanayohusiana na tumori, yanayosaidia kuelewa athari yao ndani ya mazingira ya tumori.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     Myeloid cell populations play a critical role in lung cancer progression. Here, the authors use scRNA-seq and spatial transcriptomics to identify changes in the phenotype of macrophages within the tumour microenvironment.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1112">
      Oncology and Carcinogenesis
     </kwd>
     <kwd content-type="term" vocab-term-identifier="1107">
      Immunology
     </kwd>
    </nested-kwd>
   </kwd-group>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        https://doi.org/10.13039/100010663
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      CONTEXT 101043559
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Cvejic
       </surname>
       <given-names>
        Ana
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        Cancer Research UK (CRUK)
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        https://doi.org/10.13039/501100000289
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      CTRQQR-2021\100012
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Cvejic
       </surname>
       <given-names>
        Ana
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        Open Targets (OTAR2060); Core support grants from the Wellcome Trust and Wellcome Sanger Institute and both Wellcome and the MRC to the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute (203151/Z/16/Z); European Research Council (CONTEXT 101043559); Cancer Research UK Cambridge Institute (CRUK CI) (Grant # CTRQQR-2021\100012).
       </institution>
      </institution-wrap>
     </funding-source>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      4388
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      5
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      13
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_48700.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Maarufu
   </title>
   <p id="Par3">
    Sita kifupi ni kasi ambacho linatambuliwa mara ya pili kwa mara kubwa na linahusisha ufarukaruku wa watu duniani kwa sababu ya maradhi, na uwiano wa 5 miaka wa kuzingatia ni ~6% kwa wataalamu ambao maradhi yao imekuwa mara ya mwisho
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Sita kifupi (NSCLC) ni aina ya kasi ambayo yanatambuliwa mara kubwa zaidi (~85% ya matukio yote), ili kukaenda kwa sita kidogo (15% ya matukio yote)
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
    </sup>
    . Sita kifupi ni maradhi yanayohitaji kujitambua, ambayo mazingira ya tumori yanahitaji kujitegemea na nyuzi za macrophages (Mɸ) yanayohitaji kujitegemea katika uendelezaji wa maradhi. Kwa kuzingatia, nyuzi za tumori za Mɸ (TAMs) yanaweza kuchukua rohi mbili, kusaidia uendelezaji wa tumori kwa kuchoma usimamizi wa usimamizi, kusimamiza angiogenesis, na kusaidia kurejelea usimamizi wa mifumo, lakini pia kuchoma tumori kwa kusimamiza usimamizi na kujitambua na kuchoma nyuzi za cancer
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Uhusiano wa kibinafsi kati ya sita kifupi na Mɸ yanayohusu muhimu ya kuelewa ushirikiano wao wa kibinafsi ili kujenga mbinu za chafi za kifaa zaidi.
   </p>
   <p id="Par4">
    Kwenye NSCLC, adenocarcinoma (LUAD) ni aina ya histological yanayotambuliwa mara kubwa zaidi, ili kukaenda kwa squamous-cell carcinoma (LUSC). Lobectomy (i.e., resection ya anatomi ya lobu ya mifupa) ni mara hii ya kawaida ya kujitambua kwa maradhi ya awali za NSCLC (stage I/II), wakati wataalamu ambao maradhi yao yamekuwa yasiwezi kujitambuliwa stage III au metastatic stage IV NSCLC huwatambuliwa kwa mchanganyiko wa chemotherapy na neoadjuvant yanayohusiana na vascular endothelial growth factor (VEGF) au nyuzi za kurejelea usimamizi (ICIs) kama PD1, PDL1 na CTLA4. Miamala yanayotofautiana yanayotolewa katika miaka ya mwisho ya kuzingatia biomarkers yanayohusiana na kuzingatia yanayohifadhiwa njia ya mbinu za chafi za jadisi katika maeneo ya targeted therapy na immunotherapy kulingana na histology ya tumori na PDL1 expression
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
    </sup>
    .
   </p>
   <p id="Par5">
    Namba kubwa ya utafiti zimechukua teknolojia ya mikakati ili kuzingatia mabadiliko ya transcriptional katika NSCLC
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Zile zimezitambua mazingira ya tumori ya mifupa zinazohusu funzi mbalimbali za T-cell yanayohusiana na anwani ya wataalamu, umuhimu wa tofauti ya B cells katika NSCLC kwa mbinu ya anti-tumour, aina mbalimbali za nyuzi za myeloid yanayohusiana na tumori, yanayotajzia kama mbinu mpya ya immunotherapy, na pia uhusiano wa nyuzi za neutrophils yanayohusiana na mifupa na kuzingatia anti-PDL1
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     ,
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     ,
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
    </sup>
    . Zile zilipia zaidi zilizitambua tofauti ya tumori na mabadiliko ya nyuzi katika tumori za mara ya mwisho na metastatic tumori na pia mabadiliko ya tumori yanayohusiana na mbinu ya tumori kwa nyuzi ya cancer kwa aina ya primitive
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
    </sup>
    . Katika namba kubwa ya utafiti hizi, namba chache ya mikakati zilianalizwa kwa kila mtaalamu, na mara nyingi hakuwa kujitambuliwa kwa njia ya kizazi cha kizazi cha mifupa yanayohusiana na mifupa yanayosiwezi kuzingatia, hivyo kurejelea kuzingatia tofauti ya biological katika tumori na mifupa yanayohusiana. Pia, kwa tofauti, LUAD na LUSC zilihitajiwa kama kizazi moja kwa kizazi, hivyo kurejelea kuzingatia anwani ya kizazi cha kizazi cha maradhi ambazo yanayotofautiana kwa njia ya molecular na pathological. Ingawa teknolojia ya single-cell RNA-seq (scRNA-seq) yanaweza kuzingatia aina ya nyuzi na hali zao kwa upana wa kifupi kwenye mifupa, hawana uwezo wa kuzingatia tofauti za spatial au kuzingatia mazungumzo ya nyuzi na ligands na receptors yanayohusiana na mazungumzo haya. Hivyo, kurejelea uwezo wetu wa kuzingatia kwa kifupi mazingira ya tumori (TME) na tofauti ya mazungumzo ya nyuzi kwenye TME
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
    </sup>
    .
   </p>
   <p id="Par6">
    Kuendelea kuzingatia tofauti zilizotolewa, tulizungumzia data ya scRNA-seq kutoka kwa mikakati 900,000 kutoka kwa watu 25 ambao hawejatolewa dawa na LUAD au LUSC na spatial transcriptomics kutoka kwa watu 8 ili kuzingatia tofauti katika uhusiano wa nyuzi katika tumori na mifupa yanayohusiana. Tulizungumzia zaidi aina za Mɸ na mabadiliko ya molecular yanayoyofiki katika mazingira ya tumori, baadhi yanayohusiana na aina yanayotolewa katika Mɸ wakati wa utahadhili wa kizazi cha kizazi.
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Natija
   </title>
   <sec id="Sec3">
    <title>
     ScRNA-seq na ramani ya transcriptomics ya maeneo ya NSCLC
    </title>
    <p id="Par7">
     <fig id="Fig1" position="float">
      <label>
       Fig. 1
      </label>
      <caption xml:lang="en">
       <title>
        Single-cell transcriptomics reveal the heterogeneity of NSCLC.
       </title>
       <p>
        <bold>
         A
        </bold>
        Mwongozo wa utafiti. Mikakati ya nyuzi ya kifupi kutoka kwa nyuzi ya tumori iliyotolewa, nyuzi ya kifupi karibu (background) na nyuzi ya mifupa ya kifupi kutoka kwa wateja waliotokuka wamekuwa na CD45+ au CD235− na zimejulikana kwa scRNA-seq. Vizuri ya nyuzi ya kifupi ya tumori, background na nyuzi ya kifupi ya mifupa ya kifupi iliyotokuka zimezuliwa kwa 10x Visium spatial transcriptomics.
        <bold>
         B
        </bold>
        Mwongozo wa kundi. Alama zinaonyesha watu wakiwa wateja na utafiti zilizofanyika.
        <bold>
         C
        </bold>
        UMAP projection ya tumori na data ya background+healthy ya kujumla.
        <bold>
         D
        </bold>
        Dotplot ya gene zinazohusiana na aina mbalimbali za nyuzi kwenye sampuli za tumori.
        <bold>
         E
        </bold>
        Contour plot yanayonyesha uhusiano wa kutoa kati ya gene za myeloid (
        <italic>
         LYZ, CD68, MRC1
        </italic>
        ) na gene za epithelial (
        <italic>
         EPCAM
        </italic>
        ) katika AT2 cells (44,399 nyuzi), CAMLs (2520 nyuzi) na AIMɸ (16,120 nyuzi). Gene zinazohusiana na kutoa zimezatengenezwa, zimezakubalika na zimezatengenezwa kwa log.
        <bold>
         F
        </bold>
        Boxplot yanayonyesha gene zinazohusiana na kutoa zimezatengenezwa, zimezakubalika na zimezatengenezwa kwa log ya gene za myeloid (
        <italic>
         LYZ, APOE, CD68, MRC1
        </italic>
        ) na gene za epithelial (
        <italic>
         EPCAM, KRT8, KRT19
        </italic>
        ) katika AT2 cells, CAMLs na AIMɸ. Boxes: quartiles. Whiskers: 1.5× interquartile range.
        <bold>
         G
        </bold>
        Nisaba ya nyuzi za kifupi yanayohusiana na tumori na background, iliyohesabiwa ndani ya CD235− enrichment. Mipango yanayonyesha uongezi (↑) au ukato (↓) katika tumori kulingana na background. Mipango ya kawaida kati ya watu wawili kwa Wilcoxon rank test ya kawaida na Bonferroni correction ya tofauti nyingi. **
        <italic>
         P
        </italic>
        &lt; 0.01. Mipango bila asterisks yanayonyesha aina ya nyuzi iliyopatikana tu katika tumori au background.
        <bold>
         H
        </bold>
        Nisaba ya nyuzi za kifupi yanayohusiana na tumori na background, iliyohesabiwa ndani ya nyuzi za kifupi zote zilizohusiana na CD235- enrichment. Mipango yanayonyesha uongezi (↑) au ukato (↓) katika tumori kulingana na background. Mipango ya kawaida kati ya watu wawili kwa Wilcoxon rank test ya kawaida na Bonferroni correction ya tofauti nyingi. *
        <italic>
         P
        </italic>
        &lt; 0.05, **
        <italic>
         P
        </italic>
        &lt; 0.01, ***
        <italic>
         P
        </italic>
        &lt; 0.001. Mipango bila asterisks yanayonyesha aina ya nyuzi iliyopatikana tu katika tumori au background.
        <bold>
         I
        </bold>
        Nisaba ya nyuzi za NK, DC, B, T na macrophage yanayohusiana na tumori na background, iliyohesabiwa ndani ya CD235- enrichment. Mipango yanayonyesha uongezi (↑) au ukato (↓) katika tumori kulingana na background. Mipango ya kawaida kati ya watu wawili kwa Wilcoxon rank test ya kawaida na Bonferroni correction ya tofauti nyingi. ***
        <italic>
         P
        </italic>
        &lt; 0.001. Mipango bila asterisks yanayonyesha aina ya nyuzi iliyopatikana tu katika tumori au background.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-48700-8/41467_2024_48700_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Tumori yanapokata aina mbalimbali za nyuzi za usimamizi na nyuzi za si usimamizi zaidi kuliko mazingira ya mifupa ya karibu
    </title>
    <p id="Par8"/>
    <p id="Par9"/>
    <p id="Par10">
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="en">
       <title>
        Integrated single cell and spatial transcriptomics uncovers different interaction networks in LUAD and LUSC.
       </title>
       <p>
        <bold>
         A
        </bold>
        Heatmap yanayonyesha uhusiano wa Pearson kati ya nisaba ya aina ya nyuzi ya kifupi kwa kila aina ya nyuzi ya kifupi (iliyohesabiwa ndani ya CD235− enrichment). Rangi inaonyesha thamani ya uhusiano wa Pearson, asterisks yanayonyesha daraja ya muhimu ya mipango ya uhusiano ya kawaida ya Pearson (*
        <italic>
         P
        </italic>
        &lt; 0.05, **
        <italic>
         P
        </italic>
        &lt; 0.01, ***
        <italic>
         P
        </italic>
        &lt; 0.001).
        <bold>
         B
        </bold>
        Heatmap yanayonyesha namba ya LR interactions kati ya nyuzi zote zilizohusiana na aina mbalimbali za nyuzi katika LUAD (kushoto) na LUSC (kulia). Mipango zilizofanyika kwa njia ya hierarchical clustering kwa kutumia njia ya complete linkage kwa masafu ya euclidean.
        <bold>
         C
        </bold>
        Sankey diagram yanayonyesha mipango ya tumori katika LUAD na LUSC kwa ICIs zilizotambuliwa kwa cellphoneDB. Rangi ya mstari inaonyesha aina ya LR interaction iliyopatikana katika LUAD tu (orange), LUSC tu (green) au katika maradhi mawili (blue).
        <bold>
         D
        </bold>
        Dotplot ya gene za ICI na aina mbalimbali za nyuzi zilizotambuliwa kwa (
        <bold>
         C
        </bold>
        ), zilizotambuliwa kwa aina ya tumori. Ukubwa wa kila dot inaonyesha nisaba ya nyuzi katika kundi kinyume cha gene, wakati rangi inaonyesha thamani ya kutoa ya gene zinazohusiana na kutoa zimezatengenezwa, zimezakubalika na zimezatengenezwa kwa log katika kila kundi.
        <bold>
         E
        </bold>
        Sankey diagram yanayonyesha mipango ya tumori katika LUAD na LUSC kwa VEGFA/B interactors zilizotambuliwa kwa cellphoneDB. Rangi ya mstari inaonyesha aina ya LR interaction iliyopatikana katika LUAD tu (orange), LUSC tu (green) au katika maradhi mawili (blue).
        <bold>
         F
        </bold>
        Sankey diagram yanayonyesha mipango ya tumori katika LUAD na LUSC kwa EGFR interactors zilizotambuliwa kwa cellphoneDB. Rangi ya mstari inaonyesha aina ya LR interaction iliyopatikana katika LUAD tu (orange), LUSC tu (green) au katika maradhi mawili (blue).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-48700-8/41467_2024_48700_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     LUAD na LUSC yana uhusiano wa aina ya nyuzi kwa kutosha lakini yanavyotumia mitandao mbalimbali ya uhusiano wa nyuzi-nyuzi
    </title>
    <p id="Par11"/>
    <p id="Par12"/>
    <p id="Par13">
     Kati ya L–Rs ambazo zilizotambuliwa kwa ufumbuzi katika LUAD na LUSC tulipata mara kadhaa za mara ambazo zilikuwa zinajulikana kwenye ishara za angiogenic kati ya aina mbalimbali za nyuzi za myeloid kama vile
     <italic>
      VEGFA/B-FLT1, VEGFA-KDR
     </italic>
     na
     <italic>
      VEGFA-NRP1/2
     </italic>
     <sup/>
     . Ingawa
     <italic>
      VEGFA
     </italic>
     na
     <italic>
      VEGFB
     </italic>
     zilikuwa zinajulikana kwenye LUAD na LUSC, vikabili vyao vilikuwa vinajulikana mara zaidi katika LUAD, hasa katika fibroblasts (Fig.
     <xref ref-type="fig" rid="Fig2">
      2E
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      4E
     </xref>
     ). Vilevile, tulipata uhusiano wa kujulikana kwa mara kati ya ligands za
     <italic>
      EGFR
     </italic>
     kwenye AT2 na nyuzi za epithelial yanayokimbia, kama vile
     <italic>
      EGFR-EREG
     </italic>
     ,
     <italic>
      EGFR-AREG
     </italic>
     ,
     <italic>
      EGFR-HBEGF
     </italic>
     na
     <italic>
      EGFR-MIF
     </italic>
     , ingawa MIF ilikuwa inajulikana mara zaidi katika nyuzi za LUSC (Fig.
     <xref ref-type="fig" rid="Fig2">
      2F
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      4F
     </xref>
     ). Mwishowe, tulipata ishara muhimu za kusimamia kwenye nyuzi za lymphoid, kama vile
     <italic>
      CD40-CD40LG
     </italic>
     ,
     <italic>
      CD2-CD58
     </italic>
     ,
     <italic>
      CD28-CD86
     </italic>
     ,
     <italic>
      CCL21-CCR7
     </italic>
     , na
     <italic>
      TNFRSF13B/C-TNFSF13B
     </italic>
     (
     <italic>
      TACI/BAFFR-BAFF
     </italic>
     ) (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      4G
     </xref>
     ), ambazo mara nyingi yanajulikana kwenye upatikanaji wa nyuzi za lymphoid yanayofaa kwa kawaida kwa B cells, T cells, na DCs i.e., tertiary lymphoid structures (TLS). TLS mara nyingi yanajulikana kwenye uzalishaji wa muda mrefu bila maradhi katika NSCLC
     <sup>
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Unganisho wa scRNA-seq na transcriptomics ya maeneo ya kujihusisha L–R katika mazingira ya tumori
    </title>
    <p id="Par14">
     Kati ya L–Rs ambazo zilizotambuliwa kwa ufumbuzi na aina za nyuzi zao zilizokutana, zilizohesabiwa kulingana na uhusiano wa kujulikana kwa mara kati ya geni katika mikakati ya aina ya nyuzi kutoka kwa dataset ya scRNA-seq kwa kutumia CellPhoneDB. Hata hivyo, ili kujulikana uhusiano wa kibinadamu muhimu, ni muhimu kuhakikisha aina za nyuzi zilizotambuliwa kama zinazokutana ni kwa kweli zinazokutana kwa kifisikali. Ili kufanya hivyo, tulipenda kujua jinsi mikakati ya aina za nyuzi zilizotambuliwa kwa scRNA-seq zinazotolewa kwenye sehemu za tissue. Tuliamua njia ya kujenga kulingana na scRNA-seq ya sampuli za tumori na background pamoja na profile ya spatial transcriptomic (STx) ya sehemu za tumori na background za tissue za fresh frozen. Tulipata 10× Visium kwenye sehemu mbili yanayofuata kwa kawaida, ya 10-µm, kutoka kwa watu 8, saba ambao zilikuwa zimeunganishwa na sampuli zilizotumika kwa scRNA-seq. Tulianaliza sehemu 36 mara kwa kawaida (
     <italic>
      n
     </italic>
     <sub>
      tumour
     </sub>
     = 20,
     <italic>
      n
     </italic>
     <sub>
      background
     </sub>
     = 16) na umi count wa 6894/spot katika tumori na 3350/spot katika background. Pia, tulitumia cell2location na expression profiles ya aina ya nyuzi kutoka kwa dataset yako ya scRNA-seq ili kuhakikisha mikakati ya aina ya nyuzi kwenye tissue (Fig.
     <xref ref-type="fig" rid="Fig3">
      3A
     </xref>
     , tazama “Methods”)
     <sup>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
     </sup>
     .
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="sw">
       <title>
        10x Visium huchukua hali ya colocalization ya ligand–receptor muhimu.
       </title>
       <p>
        <bold>
         A
        </bold>
        Sura za maeneo yanayonyesha kiasi cha mikakati ya AT2 cells, AIMɸ na Tregs kulingana na maeneo ya tumori.
        <bold>
         B
        </bold>
        Nisaba ya mikakati ya nyuzi (kushoto) na mikakati yanayohusu kawaida (kulia) yanayohesabiwa kulingana na kiasi cha mikakati kwa cell2location katika maeneo ya tumori na maeneo ya background. Nyuzi zilizogrupwa kulingana na anotisho zao za kawaida. Mipasho yanayohusu mizizi yanayohusu kuongeza (↑) au kurejea (↓) katika tumori, kulingana na background. Mipasho ya kawaida yanayofanyika kwa tuzo mbili za Wilcoxon rank test na Bonferroni correction kwa tofauti nyingi. *
        <italic>
         P
        </italic>
        &lt; 0.05, **
        <italic>
         P
        </italic>
        &lt; 0.01, ***
        <italic>
         P
        </italic>
        &lt; 0.001. Mipasho bila nyuzi yanayohusu kwamba aina ya mikakati iliyopatikana tu katika tumori au background. Tafadhali tazama Supplementary Data
        <xref ref-type="supplementary-material" rid="MOESM5">
         13
        </xref>
        na
        <xref ref-type="supplementary-material" rid="MOESM5">
         14
        </xref>
        kwa
        <italic>
         P
        </italic>
        values zinazohusiana.
        <bold>
         C
        </bold>
        Heatmap ya colocalization ya LR. Uhusiano wa co-expression wa pamoja ya LR gene iliyohesabiwa kwa kila spot kwa maeneo yote, na nisaba ya spots yanayocolocalize na yanayohusu kawaida katika tumori na background iliyohusishwa kwa
        <italic>
         χ
        </italic>
        <sup>
         2
        </sup>
        test iliikufuata Bonferroni multiple comparison correction. Vifaa vya dark-grey vinayohusu kwamba nisaba ya gene pairs yanayocolocalize iliyotofautiana kwa njia kubwa katika tumori na background. Anotisho za mstari ya kijani yanayohusu LR pairs yanayokuwa na maana katika mara mawili au zaidi kati ya wateja wawili na nne. Anotisho za mstari yanayohusu aina ya tumori.
        <bold>
         D
        </bold>
        Boxplot yanayonyesha nisaba ya LR pairs yanayocolocalize yanayohusu kawaida katika tumori na background kwa kila maeneo yanayohusishwa.
        <italic>
         N
        </italic>
        = 8 wateja. Mipaka yameplot katika mifano ya default kwa Python Seaborn package, i.e., mipaka yanayonyesha quartiles na mikakati ya whisker yanayokuwa mara 1.5 ya interquartile range. Data ya source imeelezwa kama Source Data file.
        <bold>
         E
        </bold>
        Sura za maeneo yanayonyesha maeneo ya spots yanayocolocalize katika tumori (jumla) na background (chini), kwa
        <italic>
         NRP1-VEGFA, NECTIN2-TIGIT, PD1-PDL1, CD96-NECTIN1
        </italic>
        na
        <italic>
         HAVCR2-LGALS9
        </italic>
        . Maeneo yanayohusishwa kutoka kwa mteja mmoja.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-48700-8/41467_2024_48700_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par15"/>
    <p id="Par16"/>
   </sec>
   <sec id="Sec7">
    <title>
     CAMLs yanapokata athari za tofauti ya namba ya nusukio (CNAs) yanayofanana na nyuzi za tumori
    </title>
    <p id="Par17"/>
    <p id="Par18">
     Analizi kwa kutumia CopyKAT iliyoonyesha tofauti kubwa za CNAs kwa kila mgonjwa katika mazingira ya tumori (Fig.
     <xref ref-type="fig" rid="Fig4">
      4A
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      5A
     </xref>
     ) lakini si katika mazingira ya nyuma. Kwenye sampuli kati ya tumori, CNAs iliyotambuliwa katika AT2 na AT2 zinazokukua mzunguko, na katika baadhi ya watu wanaotofautiana, tofauti za genetiki hizi ilishirikiwa kati ya AT2/AT2 zinazokukua mzunguko na nyuzi za epithelial zinazohusiana, inayohusu uhusiano wa mzunguko wa tofauti za epithelial (Fig.
     <xref ref-type="fig" rid="Fig4">
      4A
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      5A
     </xref>
     ). Tulipatia athari hii kwa kutumia Partition-Based Graph Abstraction (PAGA)
     <sup>
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
     </sup>
     kwa kuzingatia mazingira ya tumori. PAGA ilionyesha uhusiano wa mzunguko wa tofauti kati ya AT2 cells, AT2/epithelial cells zinazokukua mzunguko, na nyuzi za epithelial zinazohusiana kwenye mwisho moja na nyuzi za epithelial zinazokuzinga na nyuzi za epithelial zinazokukua mzunguko kwenye mwisho mwingine (Fig.
     <xref ref-type="fig" rid="Fig4">
      4B
     </xref>
     ). Pia, uhusiano wa kihistoria ulioulizwa kwa kuhakikisha uhusiano kati ya viwango vya tumori vilivyotambuliwa na pathologist na AT2 na AT2 zinazokukua mzunguko vilivyotambuliwa na cell2location, inayohusu hali yao ya tumori (Fig.
     <xref ref-type="fig" rid="Fig4">
      4C
     </xref>
     ). Uhusiano wa chache ulioulizwa kwa nyuzi za epithelial zinazohusiana (Fig.
     <xref ref-type="fig" rid="Fig4">
      4C
     </xref>
     ). Athari za tofauti katika uhusiano wa gene (DEA) ya AT2 cells kutoka kwa tumori kulingana na nyuma ilionyesha upatikanaji zaidi za gene zinazohusiana na hypoxia, mazingira ya TP53, na kubadilika kwa mazingira ya metabolismu katika tumori. AT2 cells katika tumori ilionyesha upatikanaji zaidi za gene zinazohusiana na glycolysis na oxidative phosphorylation (Fig.
     <xref ref-type="fig" rid="Fig4">
      4D
     </xref>
     na Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM5">
      16
     </xref>
     ). Ingawa muhimu ya glycolysis katika nyuzi za tumori imejulikana vizuri, iliyotambuliwa hivi karibuni kwamba NSCLC ya binadamu huendelea kutumia glucose na lactate kusaidia mazingira ya tricarboxylic acid (TCA) cycle
     <sup>
      <xref ref-type="bibr" rid="CR39">
       39
      </xref>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     . Pia, iliyotambuliwa kwamba AT2 cells katika tumori ilionyesha upatikanaji zaidi za
     <italic>
      LYPD3
     </italic>
     kulingana na AT2 cells katika nyuma (log2FC = 2.04,
     <italic>
      P
     </italic>
     <sub>
      adj
     </sub>
     = 0.039, Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM5">
      16
     </xref>
     ), protini ya kujifungua ambayo imejulikana kwa mara nyingi kuhusu athari hasi katika NSCLC na inaendelea kujitambuliwa katika utafiti wa kwanza na wa mwisho
     <sup>
      <xref ref-type="bibr" rid="CR41">
       41
      </xref>
      ,
      <xref ref-type="bibr" rid="CR42">
       42
      </xref>
     </sup>
     .
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="sw">
       <title>
        CAMLs hushiriki CNAs ya tumori na huchukua hali ya colocalization na mikakati ya tumori.
       </title>
       <p>
        <bold>
         A
        </bold>
        Tathmini ya CNA. Sura yanayonyesha mifaa ya chromosomal gains (mstari ya nyekundu) na losses (mstari ya bluu) yanayohesabiwa na CopyKat kwa kila mwili wa chromosome kwa aina mbalimbali za mikakati na wateja katika dataset ya tumori. Nyuzi zote zilizohusu kawaida zilizogrupwa kwa ajili ya plotting.
        <bold>
         B
        </bold>
        PAGA graph yanayohusishwa kwa diffusion maps (force-directed layout—FLE embedding) yanayohesabiwa kwa mikakati yanayohusu kawaida katika tumori.
        <bold>
         C
        </bold>
        Mipaka ya mwisho tatu—Anotisho za kawaida za pathologist aliyealama, yanayonyesha maeneo ya tumori (kushoto), binning ya maeneo ya tumori kwenye spots ya Visium (kati) na spots yanayopata QC (kulia). Mipaka ya mwisho tatu—Tathmini ya cell2location kwa AT2 cells (kushoto), Cycling AT2 cells (kati) na Atypical epithelial cells (kulia) kwenye maeneo haya, yanayohusishwa kwa anotisho ya pathologist kwa tumori (contour ya kijani).
        <bold>
         D
        </bold>
        Overrepresentation analysis kwa gene ontology—biological processes (GO:BP) na REACTOME database kwa clusterProfiler R package, kwa DEGs yanayohusu kawaida kwa AT2 cells katika tumori na background. Data ya source imeelezwa kama Source Data file.
        <bold>
         E
        </bold>
        Mipaka ya CNA katika AT2 na CAMLs kutoka kwa tumori ya mteja mmoja. Bars yanayonyesha nisaba ya mikakati yanayohusu chromosomal gains (bar ya nyekundu) au losses (bars ya bluu) katika maeneo ya chromosomal maalum.
        <bold>
         F
        </bold>
        Scatterplot ya KL divergence kwa losses (
        <italic>
         x
        </italic>
        axis) na gains (
        <italic>
         y
        </italic>
        axis) kati ya aina mbalimbali za mikakati katika dataset ya tumori yanayohesabiwa kwa kawaida ya gains na losses yao. Nyuzi zote zilizohusu kawaida zilizogrupwa kwa ajili ya plotting.
        <bold>
         G
        </bold>
        Sura za maeneo yanayonyesha kiasi cha mikakati yanayohesabiwa na cell2location kwa AT2 cells na CAMLs kwenye maeneo matatu yanayohusishwa katika tumori.
        <bold>
         H
        </bold>
        Hierarchical clustering ya uhusiano wa correlation distance yanayohesabiwa kwa kawaida ya mikakati (kama iliyohesabiwa na cell2location) kwa spots yanayopata QC katika maeneo yote ya tumori.
        <bold>
         I
        </bold>
        Non-negative matrix factorisation yanayohusishwa kwa tathmini ya q05 ya kawaida ya mikakati kwa spots yanayopata QC (kama iliyohesabiwa na cell2location) katika maeneo yote ya tumori.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-48700-8/41467_2024_48700_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par19">
     Kwa kushindana, aina ya CAMLs pia iliyotambuliwa na tofauti kubwa za CNAs zinazohusiana na AT2 cells na AT2 zinazokukua mzunguko kutoka kwa mgonjwa mmoja (Fig.
     <xref ref-type="fig" rid="Fig4">
      4A, E
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      5A, B
     </xref>
     ). Kukabiliana na tofauti ya usambazaji wa genomic gain na loss kati ya aina za nyuzi kwa njia yenye athari ya takwimu, tulihesabi Kullback–Leibler (KL) divergence (Fig.
     <xref ref-type="fig" rid="Fig4">
      4F
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      5C
     </xref>
     ). CAMLs ilikuwa na thamani za KL divergence zinazohusiana na nyuzi za tumori zinazohusiana na CNAs, kwa hivyo inayathibitisha uhusiano wa tofauti za CNAs zao (Fig.
     <xref ref-type="fig" rid="Fig4">
      4F
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      5C
     </xref>
     ). Ingawa CAMLs ilikuwa na uhusiano wa gene za myeloid na gene za epithelial (Fig.
     <xref ref-type="fig" rid="Fig1">
      1D–F
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      1D
     </xref>
     ), ilikuwa na thamani ya doublet score ya chache na ilishiriki tofauti za CNAs zinazohusiana na nyuzi za tumori, tuliaminiwa kwamba nyuzi hizi huwezi kutoa aina ya Mɸ yanayohusiana na nyuzi ya kiasili. Inawezekana kwamba Mɸ hizi walikuwa wakufanya phagocytosis au fusion.
    </p>
    <p id="Par20"/>
    <p id="Par21"/>
   </sec>
   <sec id="Sec8">
    <title>
     TAMs yanayusaidia kurejelea usimamizi wa cholesterol na madini ndani ya tumori
    </title>
    <p id="Par22">
     <fig id="Fig5" position="float">
      <label>
       Fig. 5
      </label>
      <caption xml:lang="en">
       <title>
        Tumour macrophages undergo oncofoetal reprogramming.
       </title>
       <p>
        <bold>
         A
        </bold>
        Ramani ya DEGs (nyepe) kwa AIMɸ katika tumori na nyuma ya tumori, iliyotolewa kwa kutumia kitufe cha py_DESeq2.
        <bold>
         B
        </bold>
        Tathmini ya kujulikana sana kwenye mawasiliano ya gene—mipango ya maisha kwa database ya clusterProfiler R package, kutumia DEGs zinazoweza kujulikana sana na Alveolar Mɸ na AIMɸ katika tumori na nyuma ya tumori. Data ya chanzo imepatikana kama faili ya Source Data.
        <bold>
         C
        </bold>
        IHC kwa CD68 na madini ya neutral (BODIPY 493/503) kwenye sehemu za tumori na nyuma ya tumori. Projeksi ya kipimo cha kasi cha z-stacks. Skala ya bar 50 µm.
        <bold>
         D
        </bold>
        Nyeupe ambayo imegunduliwa na ishara ya BODIPY katika tumori na nyuma ya tumori. Uhusiano wa kasi ya BODIPY imehakikishwa kwa kutumia t test ya mara mbili, kumaliza tumori na nyuma ya tumori kutoka kwa watafsiri wanaotofautiana.
        <italic>
         N
        </italic>
        = 5 watafsiri. Data ya chanzo imepatikana kama faili ya Source Data.
        <bold>
         E
        </bold>
        IHC kwa CD68 na STAB1 kwenye sehemu za tumori (kushoto) na nyuma ya tumori (kulia). Projeksi ya kipimo cha kasi cha z-stacks. Inlets zinazostahili zinaonyesha kipimo cha kasi cha kasi moja. Skala ya bar 20 µm.
        <bold>
         F
        </bold>
        Tathmini ya nyuzi za STAB1+ ndani ya nyuzi za CD68+ ya macrophages. Sehemu ya kasi ya STAB1 + CD68+ inayotolewa kama asilimia ya kasi ya CD68+ yote. Data zinazostahili zinapatikana kama thamani ya moyo na tofauti ya standard deviation (
        <italic>
         n
        </italic>
        = 3 biological replicates). Data ya chanzo imepatikana kama faili ya Source Data.
        <bold>
         G
        </bold>
        Kupiga rangi kwa CD68, STAB1 na PanCK kwenye sehemu za tumori. Projeksi ya kipimo cha kasi cha z-stacks. Inlets zinazostahili zinaonyesha kipimo cha kasi cha kasi moja. Skala ya bar 20 µm.
        <bold>
         H
        </bold>
        Tathmini ya nyuzi za STAB1 + CD68+ ndani ya nyuzi za CD68+ ya macrophages katika NSCLC. Data zinazostahili zinapatikana kama thamani ya moyo na nukta za data za kila watafsiri (
        <italic>
         n
        </italic>
        = 2 biological replicates). Data ya chanzo imepatikana kama faili ya Source Data.
        <bold>
         I
        </bold>
        Dotplot inayonyesha kipimo cha gene ya “STAB1 signature genes” kwenye nyuzi za macrophages zote na CAMLs katika tumori.
        <bold>
         J
        </bold>
        Ramani ya DEGs zinazotolewa kwa py_DESeq2 (nyepe) kwa Alveolar Mɸ vs STAB1 Mɸ katika tumori.
        <bold>
         K
        </bold>
        Tathmini ya kujulikana sana kwenye mawasiliano ya gene—mipango ya maisha kwa database ya clusterProfiler R package, kutumia DEGs kutoka kwa Alveolar Mɸ vs STAB1 Mɸ (jumla) na AIMɸ vs STAB1 Mɸ (chini) katika tumori (kushoto—zinazoweza kujulikana sana na STAB1 Mɸ; kulia—zinazoweza kujulikana sana na Alveolar Mɸ au AIMɸ). Data ya chanzo imepatikana kama faili ya Source Data.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-48700-8/41467_2024_48700_Fig5_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par23"/>
   </sec>
   <sec id="Sec9">
    <title>
     <italic>
      STAB1
     </italic>
     + Mɸ katika mazingira ya tumori yanapokata athari za oncofoetal reprogramming
    </title>
    <p id="Par24">
     Ukuaji wa kifungu kina sifa nyingi zinazoshiriki na mazingira ya tumori, kama vile ukuaji wa nyuzi kwa haraka, uwekezaji wa nyuzi, na mazingira ya kivascular yenye kasi sana. Imeshiriki hivi karibuni kuwasilishwa kwamba wakati wa kuzingatia tumori, Mɸ yanaweza kufanya oncofoetal reprogramming na kupata athari ya kutoa kama ya kifungu ambayo yanayosaidia ukuaji wa tumori na metastasis
     <sup>
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     . Ingawa baadhi ya gene za STAB1 signature zinazotolewa kwa kifungu Mɸ (kama vile
     <italic>
      STAB1
     </italic>
     ,
     <italic>
      FOLR2, SLC40A1, MERTK
     </italic>
     ,
     <italic>
      GPR34
     </italic>
     na
     <italic>
      F13A1
     </italic>
     ), tulitaka kuchunguza kama kuna tofauti zaidi za kutoa kati ya Mɸ yanayotoka kwa tumori na Mɸ yanayotolewa kutoka kwa kifungu cha mifupa wa binadamu. Kwa hiyo, tuliamua kujumlisha nyuzi za myeloid yanayotoka kwa tumori na nyuzi za mazingira kutoka kwa data yetu (
     <italic>
      n
     </italic>
     = 347,364 nyuzi) na nyuzi za myeloid na progenitor kutoka kwa data ya scRNA-seq ya kifungu cha mifupa ya binadamu yenye umuhimu (
     <italic>
      n
     </italic>
     = 6,947 nyuzi) kwa kutumia Harmony. Kisha, tulifanya Leiden clustering kwenye grafu ya jirani na kuchunguza jinsi aina za nyuzi zinapatikana ndani ya majina (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      6A, B
     </xref>
     ). Kuchunguza usimilishaji wa gene zao, tuliamua kuchunguza hierarchical clustering na kutengeneza dendrogram kwa kuchukua umbali wa correlation kati ya aina za nyuzi kwenye nafasi ya harmonised PC, kulingana na criterion ya complete linkage ya hierarchical clustering (Fig.
     <xref ref-type="fig" rid="Fig6">
      6A
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR54">
       54
      </xref>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
     </sup>
     .
     <fig id="Fig6" position="float">
      <label>
       Fig. 6
      </label>
      <caption xml:lang="en">
       <title>
        <italic>
         STAB1
        </italic>
        + Mɸ undergo oncofoetal reprogramming.
       </title>
       <p>
        <bold>
         A
        </bold>
        Tathmini ya hierarchical clustering ya uhusiano wa umbali uliyotathminiwa kwenye kila nyuzi katika maeneo ya PC ya harmonised (tumori myeloid + nyuma ya tumori myeloid + foetal lung myeloid).
        <bold>
         B
        </bold>
        Violin plot inayonyesha kipimo cha gene ya “STAB1 gene signature” kwenye nyuzi za myeloid na nyuzi za progenitor zinazotathminiwa kwenye atlas ya foetal lung ya mtu ya jumla.
        <bold>
         C
        </bold>
        Dotplot inayonyesha kipimo cha kila gene katika “STAB1 gene signature” kwenye nyuzi za macrophages zinazotathminiwa kwenye atlas ya foetal lung ya mtu ya jumla. Ukubwa wa kila dot inatafsiri asilimia ya nyuzi zinazokubali gene, wakati rangi inatafsiri kipimo cha kipimo cha kila gene katika kila cluster.
        <bold>
         D
        </bold>
        Violin plot inayonyesha kipimo cha gene ya “STAB1 gene signature” kwenye nyuzi za myeloid na nyuzi za progenitor zinazotathminiwa kwenye dataset ya MoMac-VERSE ya jumla.
        <bold>
         E
        </bold>
        Dotplot inayonyesha kipimo cha kila gene katika “STAB1 gene signature” kwenye nyuzi za macrophages zinazotathminiwa kwenye dataset ya MoMac-VERSE. Ukubwa wa kila dot inatafsiri asilimia ya nyuzi zinazokubali gene, wakati rangi inatafsiri kipimo cha kipimo cha kila gene katika kila cluster.
        <bold>
         F
        </bold>
        Violin plot inayonyesha kipimo cha gene ya “AMɸ gene signature” kwenye nyuzi za myeloid na nyuzi za progenitor zinazotathminiwa kwenye dataset ya “MoMac-VERSE” ya jumla.
        <bold>
         G
        </bold>
        Violin plot inayonyesha kipimo cha gene ya “AMɸ gene signature” kwenye nyuzi za myeloid na nyuzi za progenitor zinazotathminiwa kwenye atlas ya foetal lung ya mtu ya jumla.
        <bold>
         H
        </bold>
        Dotplot inayonyesha kipimo cha kila gene katika “AMɸ gene signature” kwenye nyuzi za macrophages zinazotathminiwa kwenye dataset ya “MoMac-VERSE”. Ukubwa wa kila dot inatafsiri asilimia ya nyuzi zinazokubali gene, wakati rangi inatafsiri kipimo cha kipimo cha kila gene katika kila cluster.
        <bold>
         I
        </bold>
        Dotplot inayonyesha kipimo cha kila gene katika “AMɸ gene signature” kwenye nyuzi za macrophages zinazotathminiwa kwenye atlas ya foetal lung ya mtu ya jumla. Ukubwa wa kila dot inatafsiri asilimia ya nyuzi zinazokubali gene, wakati rangi inatafsiri kipimo cha kipimo cha kila gene katika kila cluster.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-48700-8/41467_2024_48700_Fig6_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par25">
     Tuliona kwamba tumour cDC2 ilikuwa na usimilishaji wa kasi sana na background cDC2, wakati tumour mo-DC2 ilikuwa na usimilishaji wa kasi sana na foetal DC2 na, kwenye maeneo mengine, na background mo-DC2. Aina ya pDC kutoka kwa tumori, background na foetal lung ilikuwa na usimilishaji wa karibu. Vile vile, nyuzi za monocytes kutoka kwa tumori ilikuwa na usimilishaji na foetal classical monocytes na background monocytes. Kulingana na hilo, aina za macrophages katika tumori, na hasa
     <italic>
      STAB1
     </italic>
     + Mɸ, ilikuwa na usimilishaji na foetal macrophages
     <italic>
      . STAB1
     </italic>
     + Mɸ ilikuwa na usimilishaji wa kasi sana na foetal
     <italic>
      SPP1
     </italic>
     + Mɸ (Fig.
     <xref ref-type="fig" rid="Fig6">
      6A
     </xref>
     ), ambayo ilikuwa na kasi 80% ya nyuzi za foetal lung macrophages zinazoruhusiwa katika ref.
     <sup>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
     </sup>
     . Kulingana na hilo,
     <italic>
      SPP1
     </italic>
     + Mɸ ilikuwa na usimilishaji wa kasi sana wa “STAB1 signature genes” kulingana na aina mengine za haematopoietic (Fig.
     <xref ref-type="fig" rid="Fig6">
      6B, C
     </xref>
     ). Tahlil yetu inathibitisha idea ya kwamba monocytes ndani ya mazingira ya tumori, wakati wanaendelea kubadilika kwa anti-inflammatory macrophages, wanapata athari ya kutoa kama ya foetal macrophages. Athari ya kutoa hii ya kubadilika ilikuwa haijapatikana katika macrophages kutoka kwa nyuzi za kawaida zinazojirudia.
    </p>
    <p id="Par26"/>
    <p id="Par27"/>
   </sec>
  </sec>
  <sec id="Sec10" sec-type="discussion">
   <title>
    Mazungumzo
   </title>
   <p id="Par28"/>
   <p id="Par29">
    LUAD na LUSC, aina mbili zinazofaa zaidi za NSCLC, zina matokeo ya maambukizi yanayofarika sana na yameonyesha imara ya mafanikio yanayofaa kwa aina ya maradhi
    <sup>
     <xref ref-type="bibr" rid="CR28">
      28
     </xref>
    </sup>
    . Ingawa yanapewa uhusiano wa aina ya nyuzi, tulipata tofauti muhimu katika uhusiano wa kutoa kwa kila mara ya nyuzi za kurejelea usimamizi kati ya LUAD na LUSC, yanayohusu mafanikio ya mafanikio. Sampuli za LUAD zilikuwa na uhusiano wa mara nyingi na
    <italic>
     TIGIT
    </italic>
    na
    <italic>
     TIM3 (HAVCR2)
    </italic>
    , wakati kwenye LUSC tulipata ICI ya
    <italic>
     CD96-NECTIN1
    </italic>
    <sup/>
    . Ingawa viwango vya kliniki vya maradhi vya kibinafsi vya tofauti vinaendelea kusambaza TIGIT, hasa kwenye wateja ambao wana NSCLC, mafanikio ya TIM3 na CD96 ni vya kibaya zaidi
    <sup>
     <xref ref-type="bibr" rid="CR58">
      58
     </xref>
     <xref ref-type="bibr" rid="CR59">
      59
     </xref>
    </sup>
    . Mafanikio ya kwanza kwa mtu ya kipimo cha kwanza ya kliniki ya kubadilisha anti-CD96 ya monoclonal GSK6097608 kama monotherapy au kwa pamoja na anti-PD1 (dostarlimab) ilianza kujitambua wateja tu hivi karibuni
    <sup>
     <xref ref-type="bibr" rid="CR60">
      60
     </xref>
    </sup>
    . Pamoja pamoja, data zetu zinaonyesha kuwa wateja wa LUAD na LUSC wanaweza kufaidika kutoka kwa mafanikio ya kibinafsi yanayohusiana na ICIs kama TIM3, TIGIT na CD96.
   </p>
   <p id="Par30">
    TME ina athari muhimu ya kubadilisha kifaa na usimamizi wa Mɸ
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
    </sup>
    . Tulipata kuwa, mara kwa mara ya nyuzi yanayofaa kwa tumori, nyuzi za tumori zilikuwa na nyuzi za monocytes zinazotoa kidogo lakini zinazotoa sana nyuzi zinazotokana na monocytes, kama mo-DC2s na Mɸ za kurejelea usimamizi, yanayohusu kuwa kuna ukuaji wa monocytes kwa TME
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Uhusiano wa Mɸ za kurejelea usimamizi, hasa
    <italic>
     STAB1
    </italic>
    + Mɸ, ilikuwa na uhusiano uliyokaribisha kati ya wingi wa nyuzi za kurejelea usimamizi (NK) na T ndani ya mazingira ya tumori; na nyuzi za NK ndani ya tumori zilikuwa na usimamizi wa kurejelea usimamizi zinazotoa kidogo. Matokeo yetu yameongezeka na matokeo ya karibuni yanayohusu kuwa kusambaza nyuzi za tumori na lung Mɸ yanayohakikisha mabadiliko yao kwa athari ya kurejelea usimamizi, yanayohakikisha kurejelea nyuzi za NK kwenye TME
    <sup>
     <xref ref-type="bibr" rid="CR27">
      27
     </xref>
    </sup>
    . Mɸ zinazotoa sana nyuzi za tumori ziliruhusu gene zinazohusiana na usimamizi wa cholesterol na metabolism ya madini, sifa yanayoshirikiwa na Mɸ za kurejelea usimamizi katika data yetu. Kwa mujibu, ziliruhusu gene zinazohusiana na usimamizi, cytokines na chemokines zinazofaa kwa kurejelea nyuzi za CD8 + T, kwa hivyo zilikuwa na athari ya kurejelea usimamizi zinazotoa sana
    <sup>
     <xref ref-type="bibr" rid="CR27">
      27
     </xref>
    </sup>
    .
   </p>
   <p id="Par31"/>
  </sec>
  <sec id="Sec11" sec-type="methods">
   <title>
    Uchanganuzi
   </title>
   <sec id="Sec12">
    <title>
     Uthubiti wa kihakika na ukuaji wa mifupa
    </title>
    <p id="Par32"/>
    <p id="Par33"/>
   </sec>
   <sec id="Sec13">
    <title>
     Uchambuzi wa mifupa
    </title>
    <p id="Par34">
     Mifumo yaliniamini katika madini ya RPMI ya kumalizika (RPMI [Invitrogen] iliyozidiwa na 10% FBS [Sigma Millipore, namba ya catalogue: F9665], 2 mM L-Glutamine [Life Technologies, namba ya catalogue: 25030-024] na 100 U/ml Penicillin-Streptomycin [Thermofisher, namba ya catalogue: 15140122]) hadi kujumuisha, ambalo ilifanyika siku moja ya kumpimwa. Suspenzi ya mikakati yaliniamini kama ifuatayo: mifumo yaliniamini kwenye sahani ya petri na kuzungushwa kwa sekaa 2–4 mm na kumalizika kwenye tubi ya 1.5-ml yanayopakana na mikakati ya kujumuisha (madini ya RPMI ya kumalizika iliyozidiwa na  1 mg ml collagenase IV na 0.1 mg ml DNase I) na kuzungushwa kwa kijiti cha jirani. Mifumo yaliniamini yaliniamini kwa dakika 45 kwenye joto ya 37 °C na kuzungushwa kila dakika 15. Mifumo yaliniamini yaliniamini kwenye kijiti cha 100-μm kwenye tubi ya falcon yanayopakana na madini ya PBS ya baridi
     <sup/>
     .
    </p>
    <p id="Par35">
     Mikakati yaliniamini kwa dakika 5 kwenye joto ya 300 ×
     <italic>
      g
     </italic>
     , 4 °C na kumalizika kwenye 1× madini ya kuzingatia RBC (eBioscience) kwa dakika 2 kwenye joto ya nyumbani, baada ya hayo madini ya PBS ya baridi ya 20 ml yaliniamini kusimamiza reaksi ya kuzingatia. Mikakati yaliniamini kwenye 5% DMSO katika madini ya KOSR ya Kumbukumbu (Gibco, namba ya catalogue: 10828010) hadi kutumika zaidi
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec14">
    <title>
     FACS sorting
    </title>
    <p id="Par36">
     Siku ya kusorti FACS, mikakati yaliniamini kwa haraka kwenye joto ya 37 °C na kumalizika kwenye madini ya RPMI ya kumalizika. Uwezekano wa mikakati za kuzingatia ulifanyika kwa kutumia kitambaa cha MACS Dead Cell Removal Kit (Miltenyi Biotec) kufuata maelekezo ya mfanyabiashara. Mikakati ya damu ya nyuzi ya mafuta yaliniamini zaidi kwa chaguo la hasi kwa kutumia CD235a Microbeads (Miltenyi Biotec) na kijiti cha MACS LS (Miltenyi Biotec), kufuata maelekezo ya mfanyabiashara.
    </p>
    <p id="Par37">
     Kwa kusorti FACS, mikakati yaliniamini kwa Zombie Aqua kusimamiza mikakati ya kufa na mafuta ya mafuta kwa dakika 30 kwenye joto ya 4 °C. Mikakati yaliniamini kwa dakika 5 kwenye joto ya 300 ×
     <italic>
      g
     </italic>
     , 4 °C, kumalizika kwenye 500 μl ya 5% FBS katika PBS na kusindika kwenye vifaa vya FACS vya polypropylene.
    </p>
    <p id="Par38">
     Nyuzi za usimamizi yaliniamini kama za kuzingatia, CD45 + ; MDSC yaliniamini kama za kuzingatia, CD45 + , Lineage- (Lin: CD3, CD56, CD19), CD33 + , HLA-DR-/low (Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM5">
      22
     </xref>
     na Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      1A
     </xref>
     ). Mikakati yaliniamini kwenye tubi ya 1.5-ml, kuzingatia na kumpimwa kwa 10x scRNA-seq library preparation.
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     scRNA sequencing
    </title>
    <p id="Par39">
     Kila suspenshi ya nyuzi ilipatikana kwa RNA ya mikakati ya 3’ kwa kutumia Single Cell G Chip Kit, chemistry v3.1 (10x Genomics Pleasanton, CA, USA), kufuata maelekezo ya mfungaji. Libari zilipatikana kwa Illumina NovaSeq 6000, na kubadilishwa kwenye genome ya kihimo ya GRCh38 kwa kutumia CellRanger toolkit (version 3.1.0).
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     Uchanganuzi wa data ya scRNA sequencing
    </title>
    <p id="Par40">
     Kuunganisha sampuli nyingi, hasa kutoka kwa aina mbalimbali za maradhi na nyuzi za kawaida karibu, ni changamoto kwa sababu ya tofauti katika programu za gene kati ya sampuli. Kwa mujibu, tofauti hizi mara nyingi hufanya kushughulikia usambazaji wa kibiologiki wa kutosha wakati wa kujaribu kutoa maoni mara kwa mara. Tekniki nyingi za kuunganisha mara hivi, yanayohusiana na kurejelea tofauti za batch, yanafanya kazi kwenye ushambulikaji wa hali za nyuzi kati ya sampuli. Hata hivyo, wakati wana tamaa kurejelea tofauti tekniki, wanaweza kusababisha kusimamia tofauti biologiki halisi. Kwa hiyo, tuliamua kufanya filtrasi ya QC na kusambua doublets kwenye data ya yaunganishwa (Tumour + B/H) lakini tuliamua kuchukua sampuli kati ya tumour na B/H kwa chaguo la HVG, PCA, kurejelea tofauti za batch (kutumia Harmony), kusambua na kuzingatia.
    </p>
    <p id="Par41">
     Kuanzia matrisi ya tofauti za gene ambazo yameundwa (kwa sampuli) na protokoli ya CellRanger, tulifanya usafiri wa chini wa data ya scRNA-seq. Kwa kila output ya CellRanger (inayohusiana na kireplica tekniki na biologiki ya tumour, background na data ya kawaida) tuligeuza nyuzi ya chini sifa au droplets za kawaida kwa kutumia funksi ya
     <italic>
      barcodeRanks
     </italic>
     na
     <italic>
      emptyDrops
     </italic>
     kutumia kitufe cha R
     <italic>
      DropletUtils
     </italic>
     <sup>
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
     </sup>
     . Baada ya kusambua droplets kwa sampuli, matrisi yote ya tofauti za gene yalipatikana (tuliamua tumour, background, na sampuli za kawaida), na kudhibiti sifa (QC) ilipatikana kwenye matrisi ya yaunganishwa. Usafiri wa chini unayofuata unayotumika kwa njia za standard kwenye
     <italic>
      Scanpy
     </italic>
     framework. QC inabasiwa kwenye mitandazo matatu: jumla ya UMI (mada-taala [400, 100,000]), namba ya gene zinazopatikana (mada-taala [180, 6000]), na nisaba ya gene za mitochondrial kwa nyuzi (20% mada-taala). Tuliamua
     <italic>
      Scrublet
     </italic>
     kusambua doublets mara nyingi na kisha kuchambua matokeo kwa kutumia thamani za parametri (2 kwa namba ya kusoma chini ya nyuzi, 3 kwa namba ya nyuzi zinazopatikana chini ya gene, 85 kwa nisaba ya tofauti ya gene, na 30 kwa namba ya mawingi za kwanza zinazotumika kwa kutoa transcriptomes kabla ya kujenga grafu ya k-nearest-neighbour). Matrisi ya tofauti ya gene ya yaunganishwa na yausambua ilipatikana kubadilishwa kwa kifupi 10,000, iliikutiwa na log1p transformation
     <sup>
      <xref ref-type="bibr" rid="CR65">
       65
      </xref>
      <xref ref-type="bibr" rid="CR66">
       66
      </xref>
     </sup>
     .
    </p>
    <p id="Par42">
     Kwa kurejelea tofauti, tulipanda mizigo ya gene za tofauti kubwa (HVGs) kutoka kwa seti ya gene ya kuanzisho ya 25,718. Kuanzia chaguo la HVG, matrisi ya yaunganishwa ilipatikana kuchukuliwa kwa matrisi mbili:
     <italic>
      tumour
     </italic>
     , na background/healthy yanayojulikana kama B/H. Baada ya chaguo la HVG, 1604 gene zilipatikana kutoka kwa matrisi ya tumour na 1486 kutoka kwa B/H. Kutoka kwa mizigo haya ya HVG, tulipanda tofauti kwa kutumia Principal Component Analysis (PCA). Kisha, tulipanda PCA kwa tumour na B/H kwa kila moja na kuchukua mawingi 15, kulingana na kurejelea tofauti za Scree plot elbow rule. Matrisi ya yaunganishwa ilipatikana kubadilishwa kwa kurejelea tofauti tekniki zinazopatikana kati ya sampuli ambazo hawana asili biologiki. Tuliamua kurejelea tofauti kwa kutumia
     <italic>
      harmonypy
     </italic>
     (toleo la Python ya toleo la
     <italic>
      harmonyR
     </italic>
     ), kulingana na maelekezo ya kubadilishwa kulingana na toleo nyingine
     <sup>
      <xref ref-type="bibr" rid="CR67">
       67
      </xref>
      <xref ref-type="bibr" rid="CR68">
       68
      </xref>
     </sup>
     .
    </p>
    <p id="Par43"/>
   </sec>
   <sec id="Sec17">
    <title>
     Uhusiano wa aina ya nyuzi kati ya sampuli mbalimbali
    </title>
    <p id="Par44"/>
    <p id="Par45">
     Uhusiano wa athari ya mikakati kwa kila aina ya nyuzi ya usimamizi iliyotathminiwa kwa ushauri wa Pearson’s product-moment correlation coefficients.
    </p>
   </sec>
   <sec id="Sec18">
    <title>
     Ugeuzi wa alama
    </title>
    <p id="Par46">
     Kuona usawa katika anwani za aina ya nyuzi iliyofanyika kwa kawaida katika tumori na B/H, tulifanya anwani ya anwani kutoka kwa tumori hadi B/H kwa kutumia scArches
     <sup>
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
     </sup>
     . Kwa 828,191 nyuzi za usimamizi (464,952 katika tumori na 363,239 katika B/H) iliyotambuliwa kwa anwani zetu zisizotambulika, tulichagua seti ya kawaida ya 10,000 HVGs. Tulizamaa model ya scVI na kufanya mafunzo yake kwa data ya tumori kutumia aina za nyuzi za kawaida kama anwani, na kufanya mwanga wa scHPL (iliyotolewa kwa kitufe cha scArches, parameters zilizotengenezwa kutumia KNN classifier, 100 neighbours na kwa kutumia PCA dimensionality reduction) ili kupata hiraki ya aina za nyuzi za tumori. Kisha tulizamaa data ya B/H kwa model ya mafunzo ya maelezo ya kawaida kwa utambulisho, na kuhakikisha aina za nyuzi za B/H kulingana na hiraki ya tumori (probability threshold iliyotengenezwa kama 0.2). Mwishowe, tulikumbukumbuza aina za nyuzi iliyotambuliwa na anwani zetu zisizotambulika katika B/H kwa kutumia heatmap ili kuchora matrix ya confusion.
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     CellPhoneDB
    </title>
    <p id="Par47">
     Tulipata orodha ya kawaida ya uhusiano wa nyuzi-nyuzi uliyotambuliwa kwa tofauti katika mazingira ya tumori kwa kutumia ushauri wa ligand–receptor pairs na aina zao zilizotambulika, kwa kutumia CellPhoneDB
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     . Tulitambuliwa tumori (LUAD au LUSC), mazingira ya nyuma, na data za scRNA-seq za afya kama data seti za kawaida na kufanya CellPhoneDB kwa kawaida. Kusubiri athari ya uchunguzi wa kawaida katika njia ya kusimamiza data za kawaida kutoka kwa CellPhoneDB, tulitofautisha ligand–receptor pair ya kawaida kutoka kwa database ya CellPhoneDB ili iwe imetambuliwa kwa zaidi ya 30% ya nyuzi katika aina ya nyuzi ya kawaida ya kawaida. Orodha za ligand–receptor za mwisho zilizotambuliwa zilizofanyika zaidi kwa kutofautisha ligand–receptor pair ili athari ya log(1 + expression) ya ligand–receptor pair iwe zaidi ya 1.0, na athari ya Bonferroni-adjusted
     <italic>
      P
     </italic>
     value iwe chache zaidi ya 0.01. Kutoka kwa orodha za ligand–receptor za mwisho, ligand–receptor pairs na aina zao zilizotambulika zilizohusiana na data ya tumori zilizotambuliwa
     <sup>
      <xref ref-type="bibr" rid="CR72">
       72
      </xref>
     </sup>
     .
    </p>
    <p id="Par48">
     Kutatambuliza orodha za ligand–receptor iliyotambuliwa kwa CellPhoneDB, hatujafanya kwa data seti za kawaida kwa sababu ya changamoto ya kutengeneza CellPhoneDB statistical permutation tests kwa scRNA-seq na zaidi ya 10 nyuzi. Badala yake, tulizamaa data seti za tumori, afya na mazingira ya nyuma kwa njia ya kawaida ili athari ya aina ya nyuzi, watafsiri, na sampuli katika 50% ya data iliyotengenezwa zilizorithibitisha athari katika data ya kawaida
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     Uchanganuzi wa tofauti
    </title>
    <p id="Par49">
     Uhusiano wa athari wa gene (DEA) uliyofanyika kwa AT2 cells, anti-inflammatory macrophages na alveolar macrophages kwa kutumia anwani ya pseudo-bulk ili kusababisha tumori na mazingira ya nyuma. Pseudo-bulks zilizotengenezwa kwa kila mtaalamu kwa kuzingatia gene counts ya kawaida kwa nyuzi zote katika aina ya nyuzi zilizotambuliwa. Watafsiri 1 na 4 hawalinajali katika uchunguzi kwa sababu aina ya maradhi na stadium iliyotambuliwa hawajajulikana wakati wa uchunguzi. Kwa sababu kuna tofauti katika athari ya nyuzi kati ya data seti, tulizamaa cluster kubwa kwa kubwa kwa athari ya nyuzi chache. Rutin ya zamaa iliyotengenezwa ilifanyika mara 100, ili kuzingatia 100 data seti mpya zilizotengenezwa zilizorithibitisha data ya chache. DEA uliyofanyika kwa anwani ya pseudo-bulks ya kawaida na version ya Python ya pipeline ya
     <italic>
      DESeq2
     </italic>
     (py_DESeq2), kwa kujumlisha taarifa ya mtaalamu kama co-variate
     <sup>
      <xref ref-type="bibr" rid="CR73">
       73
      </xref>
     </sup>
     . Athari ya median adjusted
     <italic>
      p
     </italic>
     value kwa usimamizi wa Benjamini–Hochberg na median log2FC kwa kila gene iliyotambuliwa kwa athari ya tofauti (DEG) iliyotengenezwa kwa mara 100. Tulivyaathiri usawa wa chaguo hili la 100 mara kwa kuchora athari ya median
     <italic>
      p
     </italic>
     value kwa mara, ili kuthibitisha usawa wake (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      6C
     </xref>
     ). DEGs zilizotofautisha kwa median(padj)≤0.05 na |median(logFC)|≥1. Kabla ya kufanya overrepresentation analysis, gene zilizotambuliwa kwa athari ya zaidi ya 50% ya mara zilizotengenezwa zilizorithibitisha (DNAJB1, HSPA1A, HSPA1B, HSPB1, HSPE1, IGHA1, IGKC, IGLC2). DEGs zilizotumika kufanya gene ontology (GO) overrepresentation kwa kutumia kitufe cha
     <italic>
      clusterProfiler
     </italic>
     <sup>
      <xref ref-type="bibr" rid="CR74">
       74
      </xref>
     </sup>
     . Kuzingatia
     <italic>
      STAB1
     </italic>
     + Mɸ na AMɸ gene signatures, tulikumbukumbuza matokeo ya DEA na kuzingatia gene zilizotambuliwa kwa athari za zaidi na
     <italic>
      STAB1
     </italic>
     + Mɸ (au AMɸ) kulingana na aina mengine za Mɸ katika tumori.
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Ugeuzi wa mazingira—PAGA
    </title>
    <p id="Par50">
     Kuanaliza mazingira ya nyuzi ya myeloid katika dataset ya tumori, tulirekodi grafu ya jirani kutoka kwa nafasi ya 15-dimensional harmonised PCA kama yaliyotolewa juu, lakini tu ndani ya aina za nyuzi ya myeloid. Pia tulitumia PAGA kwenye grafu ya jirani kwa kutumia takwimu ya Scanpy. Kwa paraleli, tulihesabi diffusion map na tuzo yake ya force-directed kwa mazungumzo kutumia takwimu ya Pegasus
     <sup>
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      <xref ref-type="bibr" rid="CR65">
       65
      </xref>
      <xref ref-type="bibr" rid="CR75">
       75
      </xref>
     </sup>
     . Tulipo, tulipakua tuzo ya PAGA pamoja na diffusion map kwa kutumia takwimu ya scVelo. Tulitakariri mchakato mwenye mazungumzo hii lakini kwa nyuzi ambayo hawana usimamizi katika dataset ya tumori.
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     Uchanganuzi wa namba ya nusukio
    </title>
    <p id="Par51">
     Tulitumia takwimu ya CopyKAT kwenye data ya single-cell RNA-seq ili kupata anwani za namba za copy. Mchakato wa Copykat ulitengenezwa ili kupata anwani za namba za copy yanayohusiana na nyuzi kwa kila nyuzi, kwa kila mwili wa chromosome, zaidi ya hierarchical clustering ambayo mchakato wa kawaida huundia.
    </p>
    <p id="Par52">
     Anwani za namba za copy kwa kila nyuzi ziliweka kama ifuatayo: kwanza, mchakato wa CopyKAT (v1.0.5) wa kawaida ulihesabi hisabu za UMI zisizotengenezwa kwa mgonjwa/maeneo (i.e., tumori au background) fulani kwa kujumlisha viwango vya kawaida, isipokuwa kwa norm.cell.names. Viwango vya norm.cell.names vinawezisha kutoa anwani za nyuzi yanayotumika kama diploid normals yanayohusiana na kawaida wakati wa normalisation ya expression. CopyKAT ulitumia nyuzi zote zilizotolewa kama cDC2 dendritic cells, kama vile wanaotolewa katika namba nyingi zaidi kwa kila mgonjwa na kwa kujumlisha mazungumzo ya awali ya expression profiles zao zilizohusu hakuna tofauti ya namba za copy.
    </p>
    <p id="Par53">
     Baada ya kumaliza CopyKAT, hatua ya anwani za namba za copy ilitolewa ili kutoa tofauti za mwili wa chromosome katika nyuzi fulani. Tulipata maana kwamba, kwa asili ya mwili wa chromosome, tofauti ya expression ya binned-and-normalised kutoka kwa CopyKAT inapaswa kuwa tofauti sana (zaidi au chache) kuliko tofauti ya bins zote katika nyuzi zote yanayohusiana na diploid. Kwa kila mwili wa chromosome, tulimodel tofauti ya data bins zote kutoka kwa nyuzi zote yanayohusiana na diploid kama tofauti ya normal. Kila bin kwenye mwili wa chromosome fulani kutoka kwa nyuzi ya aneuploid yanayotolewa kufanyika kujumlisha tofauti hiyo. Mwishowe, wakati tofauti zaidi ya 50% za bins kwenye mwili wa chromosome fulani ni muhimu, mwili huo unatanduliwa kama imetofautiana katika nyuzi hiyo.
    </p>
    <p id="Par54">
     Mchakato uliyotolewa hapa juu unatoa anwani ya true/false yanayohusiana na kila nyuzi, kwa kila mwili wa chromosome, bila kuzungumza zaidi kati ya zaidi na chache. Kupata profile yanayohusiana na zaidi na chache kama inavyotolewa katika Fig.
     <xref ref-type="fig" rid="Fig4">
      4A
     </xref>
     , tulizungumza thamani za kila bin kwenye kila nyuzi: Ikiwa mwili umetofautiana na thamani ya expression ya bin ni hasi: −1, ikiwa mwili umetofautiana na thamani ya expression ya bin ni chanya: +1, ikiwa mwili haitofautiana: 0. Thamani za zilizotolewa zilizozungumzwa zilizofanyika kujumlisha kila bin kwa kila nyuzi ya aina fulani na kuzungumza kwa namba ya nyuzi za aina hiyo ili kupata sehemu ya nyuzi yanayohusiana na tofauti kama inavyotolewa katika Fig.
     <xref ref-type="fig" rid="Fig4">
      4A
     </xref>
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     Immunohistochemistry (IHC) na neutral lipid staining
    </title>
    <p id="Par55">
     Mifumo yiliyofungwa katika isopentane iliyofungwa kwa baridi ya dry-ice na ilizipishwa katika viali vya cryovials vya mifumo yanayofungwa kwa hewa ya kawaida mara −80 °C. Mifumo yiliyoyakanywa katika compound ya optimal cutting temperature (OCT) na yaliyotengenezwa kwa kawaida ya 10 μm kwa ubora katika cryostat iliyofungwa kwa baridi kwenye slides ya SuperFrost. Siku ya utafiti, slides ziliyofungwa kwa hewa ya nyumbani kwa dakika zaidi ya 5, kisha ziliyofungwa katika sulution ya fixation (4% PFA katika PBS) kwa dakika 20. Baada ya mashuka mitatu katika PBS, kila sehemu iliyoletwa iliyoingilishwa kwa 0.2% Triton-X100 (Sigma Aldrich) kwa dakika 10 kwa hewa ya nyumbani, iliyojulikana kwa mashuka mitatu katika PBS. Uingilishaji wa usisimuzi uliungwa kwa dakika 60 kwa hewa ya nyumbani kwa kutengeneza sehemu katika PBS + 2.5% BSA. Baada ya mashuka mitatu katika PBS, sehemu ziliyolewa iliyoingilishwa kwa antibodies za rabbit anti-CD68 (Abcam ab213363, 1:50) na mouse anti-STAB1 (Santa Cruz Biotechnology sc-293254, 10 µg/ml) katika PBS + 0.5% BSA usiku kwa 4 °C. Antibodies za kwanza ziliyotokana na sehemu ziliyomashuka mara tatu katika PBS, kisha ziliyolewa iliyoingilishwa kwa antibodies za mara ya pili (goat anti-rabbit AlexaFluor 594 na goat anti-mouse AlexaFluor 488 Abcam) 1:500 katika PBS + 0.5% BSA kwa dakika 120 kwa hewa ya nyumbani, iliyojulikana kwa mwanga. Z-stacks za immunohistochemistry za confocal mara mbili kwa kila mifumo na mifumo ya background kutoka kwa watu watatu ziliyandaliwa. Kwa kutumia software ya Fiji (ImageJ), sehemu za STAB1+ na CD68+ ziliyotengenezwa kwa automatic thresholding na ziliyohesabiwa katika kila picha ya z-stack.
    </p>
    <p id="Par56">
     Kuandaa levels ya cholesterol na neutral lipids tulizifungwa zaidi kwa kufungua mifumo na mifumo ya background kwa BODIPY™ 493/503 (Invitrogen). Baada ya mashuka mitatu katika PBS, sehemu ziliyolewa iliyoingilishwa kwa sulution ya 10 µg/ml ya BODIPY™ 493/503 katika PBS (1:100 kutoka kwa sulution ya 1 mg/ml katika DMSO) kwa dakika 15 kwa hewa ya nyumbani. Baada ya mashuka minne katika PBS, sehemu ziliyolewa iliyoingilishwa kwa dakika 90 na TrueVIEW (Vector Laboratories), ziliyomashuka kwa kutengeneza katika PBS kwa dakika 5, kisha ziliyokushuka na ziliyotengenezwa katika VECTASHIELD Vibrance™ Antifade. Sehemu ziliyopicha kwa kutumia microscope ya confocal ya Zeiss LSM 710 kwa ×20 (Plan-Apochromat ×20/0.8 M27) na ×63 (Plan-Apochromat ×63/1.40 Oil DIC M27). Tile scans ziliyotengenezwa iliyoingilishwa kwa anwani ya 3541 × 3542 microns kwa kila sehemu. ImageJ iliyotumika iliyoondoa background BODIPY signals na kuhesabi anwani ya BODIPY ya thresholded kwenye picha zilizostitch. Kupiga anwani ya BODIPY katika mifumo na background, tulitumia paired
     <italic>
      t
     </italic>
     test kwa kipimo cha mtu, baada ya kuthibitisha normal distribution ya data kwa kutumia Shapiro–Wilk test.
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     Uunganisho wa mifupa ya kifungu
    </title>
    <p id="Par57">
     Kuandaa oncofetal reprogramming ya nyuzi za myeloid katika NSCLC, tulitumia dataset ya scRNA-seq ya foetal lung myeloid cells na “MoMac-VERSE” iliyopublikwa
     <sup>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
     </sup>
     . Expression ya “STAB1 signature genes” na “AMɸ signature genes” kwa kila nyuzi za foetal lung myeloid iliyohesabiwa kwa kutumia function ya
     <italic>
      AddModuleScore
     </italic>
     katika Seurat v4.3. Kujenga foetal lung na adult lung tumour-infiltrating myeloid cells, tulitengeneza nyuzi za myeloid kutoka kwa dataset zetu za tumour na background na kutengeneza zao na dataset ya foetal lung myeloid iliyopublikwa kwa kutumia package ya Pegasus, kufuata workflow ifuatayo: (i) tofauti ya genes yanayofungwa kwa mara chache (zaidi ya 10 nyuzi), normalisation na log1p transformation, (ii) robust na highly-variable gene selection, (iii) PCA kwa optimal PC number iliyohesabiwa kwa random matrix theory (ilipata 75 PCs), (iv) batch effect correction kwa kutumia Harmony, na (v) Leiden clustering kwa neighbourhood graph. Dendrogram iliyotengenezwa kwa kutumia correlation distance kati ya aina za nyuzi kwenye harmonised PC embedding space, kufuata complete linkage criterion ya hierarchical clustering. UMAP iliyotengenezwa iliyoingilishwa kwa 2D summary kwa harmonised PC space
     <sup>
      <xref ref-type="bibr" rid="CR67">
       67
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     10x Genomics Visium spatial transcriptomics
    </title>
    <p id="Par58"/>
   </sec>
   <sec id="Sec26">
    <title>
     Uhusiano wa aina ya nyuzi na cell2location
    </title>
    <p id="Par59"/>
    <p id="Par60">
     Uhusiano wa aina ya nyuzi katika sehemu za tumori na nyuzi za mazingira zilihitajiwa kwa kujumlisha uhusiano wa q05 wa aina ya nyuzi, kama ilivyohusishwa na cell2location, kulingana na spot zinazopewa QC. Uhusiano wa aina ya nyuzi ulihitajiwa kwa kujumlisha uhusiano wa kila aina ya nyuzi kwa jumla ya uhusiano wa nyuzi zote. Tulikumbukumbusha uhusiano wa aina ya nyuzi kati ya tumori na mazingira kwa mtandao wa Wilcoxon signed-rank test, ili kusubiriwe na Bonferroni correction.
    </p>
    <p id="Par61">
     Kwenye sehemu za tumori, tulikadhaa umbali wa uhusiano kwa uhusiano wa aina ya nyuzi kulingana na spot zinazopewa, tuliamua clustering ya hierarchical kwa kujumlisha, na tulionyesha matokeo kama dendrogram. Pia, tuliamua analysis ya non-negative matrix factorisation kwa uhusiano wa q05 wa uhusiano wa aina ya nyuzi kwa kifaktari kumi na moja.
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     Uhusiano wa ligand–receptor katika maeneo
    </title>
    <p id="Par62">
     Kuandaa uhusiano wa ligand–receptor pairs kwenye 10X Visium, tulikadhaa umbali wa uhusiano wa kila gene katika LR pairs katika spot zinazopewa QC. Tulikumbuka gene inayotolewa katika spot ikiwa uhusiano wa cell2location ulikuwa juu ya median counts kwa gene hiyo katika sehemu iliyotambuliwa. Tulihesabi spot zinazopewa kwa kila LR pair ambazo zilikuwa na uhusiano au sio, kwenye sehemu za tumori na mazingira kutoka kwa mgonjwa mmoja, na kusubiriwe, tuliamua mtandao wa
     <italic>
      χ
     </italic>
     test kwenye jadwal ya contingency. Kusubiri kwa tofauti nyingi, tuliamua
     <italic>
      P
     </italic>
     value kwa kutumia Bonferroni correction yenye kibinafsi kwa LR zote zinazopanda katika tumori katika analysis ya cellphoneDB (309 * 8 mgonjwa). LR zilihitajiwa kwa uhusiano wa kutosha katika tumori ikiwa Bonferroni-adjusted
     <italic>
      P
     </italic>
     value ilikuwa chini ya 0.05 kwa mgonjwa mawili au zaidi
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     Multiplexed Immunofluorescence
    </title>
    <p id="Par63">
     Sehemu za 5 μm za NSCLC FFPE tumori ziliundwa. Cocktail ya antibodies iliyopangwa ilipewa dilutions bora ya kila antibody ya kujulikana: anti-human Stabilin-1 antibody (clone #840449, catalogue #MAB3825, R&amp;D systems) ilipewa barcode ya oligo ya kujulikana kulingana na maelekezo katika kitu ya antibody conjugation kit ya Akoya Biosciences (Conjugation kit, #7000009; Akoya) wakati human CD68 (clone #KP1, catalogue #4550113, Akoya) na human PanCK (clone AE-1/AE-3, catalogue #4150020, Akoya) ilipewa kwa kujulikana kwa barcodes ya oligo kwa mara moja kutoka kwa Akoya Biosciences. Fluorophore reporters ya kujulikana ya oligo ilipewa kutoka kwa Akoya Biosciences. Tissue multiplexed immunofluorescence staining na image acquisition ilifanyika kulingana na user guide ya Akoya Phenocycler-Fusion (PD-000011 Rev. A., Akoya). OME-TIFF files zilizundwa na ziliproseswa kwa analysis ya images.
    </p>
   </sec>
   <sec id="Sec29">
    <title>
     Uchanganuzi wa picha
    </title>
    <p id="Par64">
     Analysis ya images ya multiplexed immunofluorescence (ilizundwa kutoka kwa platform ya Akoya Phenocycler-Fusion) ilifanyika kwa kutumia Visiopharm (version 2023.09.3.15043 × 64) kwa kila sehemu ya tissue. Kwa ufupi, cell segmentation (kulingana na nuclear na cytoplasmic segmentation) ilifanyika kwa kutumia “Cell Detection, AI (Fluorescence)” (version 2023.09.3.15043 × 64) kwa maelekezo yake ya kibinafsi. Baada ya cell segmentation, “Phenoplex Guided Workflow” ya Visiopharm ilitumika. DAPI (nucleus), CD68 (cell body) na STAB1 (cell body) variables ilipewa na ilikadhaa kwa kujulikana na kusimamia cells kwa kila marker na kujenga co-occurrence matrix. Macrophages ilipewa kama [DAPI + , CD68 + ] wakati STAB1+ macrophages ilipewa kama [DAPI + , CD68 + , STAB1 + ].
    </p>
   </sec>
   <sec id="Sec30">
    <title>
     Reporting summary
    </title>
    <p id="Par65">
     Maelezo zaidi kuhusu maelekezo ya utafiti yamepatikana kwenye
     <xref ref-type="supplementary-material" rid="MOESM3">
      Nature Portfolio Reporting Summary
     </xref>
     iliyolinkwa kwa makala hii.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Acknowledgements
   </title>
   <p>
    Waziri wana heshima kwa Papworth Hospital Research Tissue Bank kwa kutoa sampuli pamoja na data, na hasa kwa D. Rassl. Waziri wana heshima kwa L. Campos kwa kutoa anwani za histologies ya tumori; A.M. Ranzoni, B. Myers na E. Panada kwa kusambaza na kusafisha sampuli; M. Nelson kwa usimamizi wa kompyuta kwa uhasama wa scRNA-Seq awali na kusimamia cell2location; Alessandro Di Tullio, GSK kwa majadiliano yanayofaa; Cancer Research UK Cambridge Institute (CRUK CI) (Grant # CTRQQR-2021\100012) Genomics Core Facility kwa huduma za kusafisha libari na kusimamia; Wellcome Sanger Institute (WSI) DNA pipelines kwa kusimamia kusimamia data; S. Leonard kutoka New Pipeline Group (NPG) kwa kusimamia data ya kusimamia awali; Cambridge NIHR BRC Cell Phenotyping Hub kwa usimamia kusimamia nyuzi. Tunasifi R. Möller, P. Rainer, na U. Tiemann kwa kusoma kwa kikali manuskripito. Utafiti huu ulikuwa unawezeshwa na Open Targets (OTAR2060, A.C.); Usimamizi wa kifupi kutoka Wellcome Trust na Wellcome Sanger Institute na pia Wellcome na MRC kwa Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute (203151/Z/16/Z, A.C.); European Research Council (CONTEXT 101043559, A.C.); Baadhi ya maoni na majadiliano yanayotolewa ni tu ya wanaotandika na hawawezi kutolewa kwa Umoja wa Ulaya au European Research Council Executive Agency. Wala Umoja wa Ulaya wala kifaa cha kutoa siri hawawezi kujulikana kwa hawana athari zao.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Author contributions
   </title>
   <p>
    A.C. alimwanga utafiti na kumshirikisha katika masuala yote ya majaribio na uhusiano. M.D.Z. alimfanya majaribio na uhusiano. H.X. alimshiriki katika uhusiano wa transcriptomics ya maeneo na kumshirikisha katika uhusiano wa data ya scRNA-seq. J.S.P. alimfanya majaribio ya Visum kwa usimamizi wa O.B. Z.S. alimshiriki katika kusimamia CellPhoneDB kwa usimamizi wa M.G. S.C.D. alimshiriki katika uhusiano wa CopyCAT. J.T. na S.C.A. alimfanya Multiplexed Immunofluorescence kwa usimamizi wa A.H. A.H. alimshiriki katika kuelewa matokeo. E.A. alimfanya DEA. A.C. na M.D.Z. walimzaa manuskripito, na waziri wote walimshiriki na kumshirikisha manuskripito.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Uthubiti wa kihakika
   </title>
   <sec id="FPar1">
    <title>
     Uthubiti wa kihakika
    </title>
    <p id="Par66">
     <italic>
      Nature Communications
     </italic>
     thanks Charles Powell and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Uvumilivu wa data
   </title>
   <p>
    The scRNA-seq and Visium datasets generated in this study are publicly available at BioStudies (
    <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/biostudies/">
     https://www.ebi.ac.uk/biostudies/
    </ext-link>
    ) with accession numbers
    <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-13526">
     E-MTAB-13526
    </ext-link>
    and
    <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-13530">
     E-MTAB-13530
    </ext-link>
    , respectively. The remaining data are available within the Article, Supplementary Information or Source Data file
    <xref ref-type="sec" rid="Sec32">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Uvumilivu wa programu
   </title>
   <p>
    The scripts used for all the analyses and to produce all the figures in the manuscript are available at
    <ext-link ext-link-type="uri" xlink:href="https://gitlab.com/cvejic-group/lung">
     https://gitlab.com/cvejic-group/lung
    </ext-link>
    and
    <ext-link ext-link-type="uri" xlink:href="https://github.com/sdentro/copykat_pipeline">
     https://github.com/sdentro/copykat_pipeline
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Uhusiano wa kujihusisha
    </title>
    <p id="Par67">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Viungo
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="other">
      Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
      <italic>
       CA. Cancer J. Clin
      </italic>
      .
      <bold>
       71
      </bold>
      , 209–249 (2021).
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Siegel
        </surname>
        <given-names>
         RL
        </given-names>
       </name>
       <name>
        <surname>
         Miller
        </surname>
        <given-names>
         KD
        </given-names>
       </name>
       <name>
        <surname>
         Jemal
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Cancer statistics, 2018
      </article-title>
      <source>
       Ca. Cancer J. Clin.
      </source>
      <year>
       2018
      </year>
      <volume>
       68
      </volume>
      <fpage>
       7
      </fpage>
      <lpage>
       30
      </lpage>
      <pub-id pub-id-type="pmid">
       29313949
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3322/caac.21442
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nicholson
        </surname>
        <given-names>
         AG
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer
      </article-title>
      <source>
       J. Thorac. Oncol.
      </source>
      <year>
       2016
      </year>
      <volume>
       11
      </volume>
      <fpage>
       300
      </fpage>
      <lpage>
       311
      </lpage>
      <pub-id pub-id-type="pmid">
       26723244
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.jtho.2015.10.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mantovani
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Allavena
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <name>
        <surname>
         Marchesi
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Garlanda
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Macrophages as tools and targets in cancer therapy
      </article-title>
      <source>
       Nat. Rev. Drug Discov.
      </source>
      <year>
       2022
      </year>
      <volume>
       21
      </volume>
      <fpage>
       799
      </fpage>
      <lpage>
       820
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XitFGjsrfI
      </pub-id>
      <pub-id pub-id-type="pmid">
       35974096
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9380983
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41573-022-00520-5
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         DeNardo
        </surname>
        <given-names>
         DG
        </given-names>
       </name>
       <name>
        <surname>
         Ruffell
        </surname>
        <given-names>
         B
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Macrophages as regulators of tumour immunity and immunotherapy
      </article-title>
      <source>
       Nat. Rev. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       19
      </volume>
      <fpage>
       369
      </fpage>
      <lpage>
       382
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXmtFKhtrw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       30718830
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7339861
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41577-019-0127-6
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Thai
        </surname>
        <given-names>
         AA
        </given-names>
       </name>
       <name>
        <surname>
         Solomon
        </surname>
        <given-names>
         BJ
        </given-names>
       </name>
       <name>
        <surname>
         Sequist
        </surname>
        <given-names>
         LV
        </given-names>
       </name>
       <name>
        <surname>
         Gainor
        </surname>
        <given-names>
         JF
        </given-names>
       </name>
       <name>
        <surname>
         Heist
        </surname>
        <given-names>
         RS
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Lung cancer
      </article-title>
      <source>
       Lancet
      </source>
      <year>
       2021
      </year>
      <volume>
       398
      </volume>
      <fpage>
       535
      </fpage>
      <lpage>
       554
      </lpage>
      <pub-id pub-id-type="pmid">
       34273294
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S0140-6736(21)00312-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Leader
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
      </article-title>
      <source>
       Cancer Cell
      </source>
      <year>
       2021
      </year>
      <volume>
       39
      </volume>
      <fpage>
       1594
      </fpage>
      <lpage>
       1609.e12
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXisVyjsLzN
      </pub-id>
      <pub-id pub-id-type="pmid">
       34767762
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8728963
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ccell.2021.10.009
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wu
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021NatCo..12.2540W
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhtVGltrfK
      </pub-id>
      <pub-id pub-id-type="pmid">
       33953163
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8100173
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-021-22801-0
      </pub-id>
      <elocation-id>
       2540
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kim
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2020
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2020NatCo..11.2285K
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXptVertbg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32385277
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7210975
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-020-16164-1
      </pub-id>
      <elocation-id>
       2285
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Guo
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2018
      </year>
      <volume>
       24
      </volume>
      <fpage>
       978
      </fpage>
      <lpage>
       985
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXht1WqsLjE
      </pub-id>
      <pub-id pub-id-type="pmid">
       29942094
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-018-0045-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2020
      </year>
      <volume>
       21
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXht1ClsrzE
      </pub-id>
      <pub-id pub-id-type="pmid">
       32580738
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7315523
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-020-02064-6
      </pub-id>
      <elocation-id>
       152
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zilionis
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species
      </article-title>
      <source>
       Immunity
      </source>
      <year>
       2019
      </year>
      <volume>
       50
      </volume>
      <fpage>
       1317
      </fpage>
      <lpage>
       1334.e10
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXntVSrt7Y%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       30979687
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6620049
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.immuni.2019.03.009
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lavin
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2017
      </year>
      <volume>
       169
      </volume>
      <fpage>
       750
      </fpage>
      <lpage>
       765.e17
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2sXnt1CmsL0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       28475900
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5737939
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2017.04.014
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Salcher
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer
      </article-title>
      <source>
       Cancer Cell
      </source>
      <year>
       2022
      </year>
      <volume>
       40
      </volume>
      <fpage>
       1503
      </fpage>
      <lpage>
       1520.e8
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XivVGjurvE
      </pub-id>
      <pub-id pub-id-type="pmid">
       36368318
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9767679
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ccell.2022.10.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maynard
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2020
      </year>
      <volume>
       182
      </volume>
      <fpage>
       1232
      </fpage>
      <lpage>
       1251.e22
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhs1GqsrzM
      </pub-id>
      <pub-id pub-id-type="pmid">
       32822576
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7484178
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2020.07.017
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Adams
        </surname>
        <given-names>
         DL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Circulating giant macrophages as a potential biomarker of solid tumors
      </article-title>
      <source>
       Proc. Natl. Acad. Sci. USA
      </source>
      <year>
       2014
      </year>
      <volume>
       111
      </volume>
      <fpage>
       3514
      </fpage>
      <lpage>
       3519
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2014PNAS..111.3514A
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2cXjtlynt7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       24550495
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3948254
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1073/pnas.1320198111
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ali
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Adams
        </surname>
        <given-names>
         DL
        </given-names>
       </name>
       <name>
        <surname>
         Kasabwala
        </surname>
        <given-names>
         DM
        </given-names>
       </name>
       <name>
        <surname>
         Tang
        </surname>
        <given-names>
         C-M
        </given-names>
       </name>
       <name>
        <surname>
         Ho
        </surname>
        <given-names>
         TH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time
      </article-title>
      <source>
       Sci. Rep.
      </source>
      <year>
       2023
      </year>
      <volume>
       13
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2023NatSR..1310544A
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXhtlKqsrnK
      </pub-id>
      <pub-id pub-id-type="pmid">
       37386095
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10310728
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41598-023-37671-3
      </pub-id>
      <elocation-id>
       10544
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Gironda
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy
      </article-title>
      <source>
       J. Transl. Med.
      </source>
      <year>
       2020
      </year>
      <volume>
       18
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXitlKitLnK
      </pub-id>
      <pub-id pub-id-type="pmid">
       33148307
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7640696
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s12967-020-02563-x
      </pub-id>
      <elocation-id>
       413
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Manjunath
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Tumor-cell–macrophage fusion cells as liquid biomarkers and tumor enhancers in cancer
      </article-title>
      <source>
       Int. J. Mol. Sci.
      </source>
      <year>
       2020
      </year>
      <volume>
       21
      </volume>
      <fpage>
       1872
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhvVejsrfL
      </pub-id>
      <pub-id pub-id-type="pmid">
       32182935
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7084898
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/ijms21051872
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Manjunath
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Circulating giant tumor-macrophage fusion cells are independent prognosticators in patients with NSCLC
      </article-title>
      <source>
       J. Thorac. Oncol.
      </source>
      <year>
       2020
      </year>
      <volume>
       15
      </volume>
      <fpage>
       1460
      </fpage>
      <lpage>
       1471
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhtVantr3E
      </pub-id>
      <pub-id pub-id-type="pmid">
       32416323
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.jtho.2020.04.034
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sutton
        </surname>
        <given-names>
         TL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Circulating cells with macrophage-like characteristics in cancer: the importance of circulating neoplastic-immune hybrid cells in cancer
      </article-title>
      <source>
       Cancers
      </source>
      <year>
       2022
      </year>
      <volume>
       14
      </volume>
      <fpage>
       3871
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XitlSls7fK
      </pub-id>
      <pub-id pub-id-type="pmid">
       36010865
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9405966
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/cancers14163871
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lotfollahi
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Mapping single-cell data to reference atlases by transfer learning
      </article-title>
      <source>
       Nat. Biotechnol.
      </source>
      <year>
       2022
      </year>
      <volume>
       40
      </volume>
      <fpage>
       121
      </fpage>
      <lpage>
       130
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhvFWqtb3O
      </pub-id>
      <pub-id pub-id-type="pmid">
       34462589
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41587-021-01001-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Collin
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Bigley
        </surname>
        <given-names>
         V
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Human dendritic cell subsets: an update
      </article-title>
      <source>
       Immunology
      </source>
      <year>
       2018
      </year>
      <volume>
       154
      </volume>
      <fpage>
       3
      </fpage>
      <lpage>
       20
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXjt12qt7w%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29313948
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5904714
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1111/imm.12888
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Jiang
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <name>
        <surname>
         Wei
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Xu
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         J
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects
      </article-title>
      <source>
       Mol. Cancer
      </source>
      <year>
       2020
      </year>
      <volume>
       19
      </volume>
      <pub-id pub-id-type="pmid">
       32680511
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7367382
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s12943-020-01234-1
      </pub-id>
      <elocation-id>
       116
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wu
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
      </article-title>
      <source>
       Nat. Cancer
      </source>
      <year>
       2022
      </year>
      <volume>
       3
      </volume>
      <fpage>
       696
      </fpage>
      <lpage>
       709
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvFGrsLzM
      </pub-id>
      <pub-id pub-id-type="pmid">
       35637401
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9236901
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s43018-022-00376-z
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mensurado
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Blanco-Domínguez
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Silva-Santos
        </surname>
        <given-names>
         B
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The emerging roles of γδ T cells in cancer immunotherapy
      </article-title>
      <source>
       Nat. Rev. Clin. Oncol.
      </source>
      <year>
       2023
      </year>
      <volume>
       20
      </volume>
      <fpage>
       178
      </fpage>
      <lpage>
       191
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXntFajsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       36624304
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41571-022-00722-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Park
        </surname>
        <given-names>
         MD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer
      </article-title>
      <source>
       Nat. Immunol.
      </source>
      <year>
       2023
      </year>
      <volume>
       24
      </volume>
      <fpage>
       792
      </fpage>
      <lpage>
       801
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXot1artrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       37081148
      </pub-id>
      <pub-id pub-id-type="pmcid">
       11088947
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41590-023-01475-4
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Relli
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Trerotola
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Guerra
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         Alberti
        </surname>
        <given-names>
         S
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Abandoning the notion of non-small cell lung cancer
      </article-title>
      <source>
       Trends Mol. Med.
      </source>
      <year>
       2019
      </year>
      <volume>
       25
      </volume>
      <fpage>
       585
      </fpage>
      <lpage>
       594
      </lpage>
      <pub-id pub-id-type="pmid">
       31155338
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.molmed.2019.04.012
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Efremova
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Vento-Tormo
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Teichmann
        </surname>
        <given-names>
         SA
        </given-names>
       </name>
       <name>
        <surname>
         Vento-Tormo
        </surname>
        <given-names>
         R
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes
      </article-title>
      <source>
       Nat. Protoc.
      </source>
      <year>
       2020
      </year>
      <volume>
       15
      </volume>
      <fpage>
       1484
      </fpage>
      <lpage>
       1506
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXjvFynsL0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32103204
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41596-020-0292-x
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="other">
      Louche, C. D. D. &amp; Roghanian, A. Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy.
      <italic>
       JCI Insight
      </italic>
      <bold>
       7
      </bold>
      , e151553 (2022).
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Camidge
        </surname>
        <given-names>
         DR
        </given-names>
       </name>
       <name>
        <surname>
         Doebele
        </surname>
        <given-names>
         RC
        </given-names>
       </name>
       <name>
        <surname>
         Kerr
        </surname>
        <given-names>
         KM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
      </article-title>
      <source>
       Nat. Rev. Clin. Oncol.
      </source>
      <year>
       2019
      </year>
      <volume>
       16
      </volume>
      <fpage>
       341
      </fpage>
      <lpage>
       355
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtVyjtrrJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       30718843
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41571-019-0173-9
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chae
        </surname>
        <given-names>
         YK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
      </article-title>
      <source>
       J. Immunother. Cancer
      </source>
      <year>
       2018
      </year>
      <volume>
       6
      </volume>
      <fpage>
       39
      </fpage>
      <pub-id pub-id-type="pmid">
       29769148
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5956851
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s40425-018-0349-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fukuhara
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study
      </article-title>
      <source>
       Cancer Immunol. Immunother.
      </source>
      <year>
       2022
      </year>
      <volume>
       71
      </volume>
      <fpage>
       1129
      </fpage>
      <lpage>
       1137
      </lpage>
      <pub-id pub-id-type="pmid">
       34596720
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00262-021-03067-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kleshchevnikov
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cell2location maps fine-grained cell types in spatial transcriptomics
      </article-title>
      <source>
       Nat. Biotechnol.
      </source>
      <year>
       2022
      </year>
      <volume>
       40
      </volume>
      <fpage>
       661
      </fpage>
      <lpage>
       671
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xht1KqsL8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35027729
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41587-021-01139-4
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liu
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Concordance of MERFISH spatial transcriptomics with bulk and single-cell RNA sequencing
      </article-title>
      <source>
       Life Sci. Alliance
      </source>
      <year>
       2023
      </year>
      <volume>
       6
      </volume>
      <fpage>
       e202201701
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2023usnb.book.....L
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXhsFalt7Y%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       36526371
      </pub-id>
      <pub-id pub-id-type="doi">
       10.26508/lsa.202201701
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="other">
      Chananchida, S., Robin, B., Ruth, S. &amp; Yvan, S. Spotless: a reproducible pipeline for benchmarking cell type deconvolution in spatial transcriptomics.
      <italic>
       eLife
      </italic>
      <bold>
       12
      </bold>
      , RP88431 (2023).
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Gao
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes
      </article-title>
      <source>
       Nat. Biotechnol.
      </source>
      <year>
       2021
      </year>
      <volume>
       39
      </volume>
      <fpage>
       599
      </fpage>
      <lpage>
       608
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhsFOitb0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33462507
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8122019
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41587-020-00795-2
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wolf
        </surname>
        <given-names>
         FA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2019
      </year>
      <volume>
       20
      </volume>
      <pub-id pub-id-type="pmid">
       30890159
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6425583
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-019-1663-x
      </pub-id>
      <elocation-id>
       59
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         DeBerardinis
        </surname>
        <given-names>
         RJ
        </given-names>
       </name>
       <name>
        <surname>
         Chandel
        </surname>
        <given-names>
         NS
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Fundamentals of cancer metabolism
      </article-title>
      <source>
       Sci. Adv.
      </source>
      <year>
       2016
      </year>
      <volume>
       2
      </volume>
      <fpage>
       e1600200
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2016SciA....2E0200D
      </pub-id>
      <pub-id pub-id-type="pmid">
       27386546
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4928883
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/sciadv.1600200
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="other">
      American Association for Cancer Research. Lactate fuels the TCA cycle in non-small cell lung cancer.
      <italic>
       Cancer Discov
      </italic>
      .
      <bold>
       7
      </bold>
      , OF10 (2017).
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hansen
        </surname>
        <given-names>
         LV
        </given-names>
       </name>
       <name>
        <surname>
         Skov
        </surname>
        <given-names>
         BG
        </given-names>
       </name>
       <name>
        <surname>
         Ploug
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Pappot
        </surname>
        <given-names>
         H
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer
      </article-title>
      <source>
       Lung Cancer
      </source>
      <year>
       2007
      </year>
      <volume>
       58
      </volume>
      <fpage>
       260
      </fpage>
      <lpage>
       266
      </lpage>
      <pub-id pub-id-type="pmid">
       17706320
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.lungcan.2007.06.025
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Willuda
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Preclinical antitumor efficacy of BAY 1129980—a novel Auristatin-based anti-C4.4A (LYPD3) antibody–drug conjugate for the treatment of non-small cell lung cancer
      </article-title>
      <source>
       Mol. Cancer Ther.
      </source>
      <year>
       2017
      </year>
      <volume>
       16
      </volume>
      <fpage>
       893
      </fpage>
      <lpage>
       904
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2sXmvFemsb0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       28292941
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1158/1535-7163.MCT-16-0474
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Gibbings
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Transcriptome analysis highlights the conserved difference between embryonic and postnatal-derived alveolar macrophages
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2015
      </year>
      <volume>
       126
      </volume>
      <fpage>
       1357
      </fpage>
      <lpage>
       1366
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28XovF2gtw%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       26232173
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4566811
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood-2015-01-624809
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         JW
        </given-names>
       </name>
       <name>
        <surname>
         Dhahbi
        </surname>
        <given-names>
         J
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods
      </article-title>
      <source>
       Sci. Rep.
      </source>
      <year>
       2021
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021NatSR..1113323C
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhs1amsrfF
      </pub-id>
      <pub-id pub-id-type="pmid">
       34172784
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8233431
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41598-021-92725-8
      </pub-id>
      <elocation-id>
       13323
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Xiao
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Eight potential biomarkers for distinguishing between lung adenocarcinoma and squamous cell carcinoma
      </article-title>
      <source>
       Oncotarget
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       71759
      </fpage>
      <lpage>
       71771
      </lpage>
      <pub-id pub-id-type="pmid">
       29069744
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5641087
      </pub-id>
      <pub-id pub-id-type="doi">
       10.18632/oncotarget.17606
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Blériot
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Chakarov
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Ginhoux
        </surname>
        <given-names>
         F
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Determinants of resident tissue macrophage identity and function
      </article-title>
      <source>
       Immunity
      </source>
      <year>
       2020
      </year>
      <volume>
       52
      </volume>
      <fpage>
       957
      </fpage>
      <lpage>
       970
      </lpage>
      <pub-id pub-id-type="pmid">
       32553181
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.immuni.2020.05.014
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR47">
     <label>
      47.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Huang
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Song
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Xu
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
      </article-title>
      <source>
       Nat. Metab.
      </source>
      <year>
       2020
      </year>
      <volume>
       2
      </volume>
      <fpage>
       132
      </fpage>
      <lpage>
       141
      </lpage>
      <pub-id pub-id-type="pmid">
       32694690
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s42255-020-0174-0
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR48">
     <label>
      48.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nugent
        </surname>
        <given-names>
         AA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge
      </article-title>
      <source>
       Neuron
      </source>
      <year>
       2020
      </year>
      <volume>
       105
      </volume>
      <fpage>
       837
      </fpage>
      <lpage>
       854.e9
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXksFWhuw%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       31902528
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.neuron.2019.12.007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR49">
     <label>
      49.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Molgora
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2020
      </year>
      <volume>
       182
      </volume>
      <fpage>
       886
      </fpage>
      <lpage>
       900.e17
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsF2qt73J
      </pub-id>
      <pub-id pub-id-type="pmid">
       32783918
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7485282
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2020.07.013
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR50">
     <label>
      50.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Khantakova
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <name>
        <surname>
         Brioschi
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Molgora
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Exploring the impact of TREM2 in tumor-associated macrophages
      </article-title>
      <source>
       Vaccines
      </source>
      <year>
       2022
      </year>
      <volume>
       10
      </volume>
      <fpage>
       943
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhslKjtL%2FL
      </pub-id>
      <pub-id pub-id-type="pmid">
       35746551
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9227554
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/vaccines10060943
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR51">
     <label>
      51.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ward
        </surname>
        <given-names>
         DM
        </given-names>
       </name>
       <name>
        <surname>
         Kaplan
        </surname>
        <given-names>
         J
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Ferroportin-mediated iron transport: expression and regulation
      </article-title>
      <source>
       Biochim. Biophys. Acta
      </source>
      <year>
       2012
      </year>
      <volume>
       1823
      </volume>
      <fpage>
       1426
      </fpage>
      <lpage>
       1433
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC38XltVehsrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22440327
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3718258
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.bbamcr.2012.03.004
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR52">
     <label>
      52.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Recalcati
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Differential regulation of iron homeostasis during human macrophage polarized activation
      </article-title>
      <source>
       Eur. J. Immunol.
      </source>
      <year>
       2010
      </year>
      <volume>
       40
      </volume>
      <fpage>
       824
      </fpage>
      <lpage>
       835
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3cXjtVWktLg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20039303
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/eji.200939889
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR53">
     <label>
      53.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sharma
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Blériot
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Currenti
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Ginhoux
        </surname>
        <given-names>
         F
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Oncofetal reprogramming in tumour development and progression
      </article-title>
      <source>
       Nat. Rev. Cancer
      </source>
      <year>
       2022
      </year>
      <volume>
       22
      </volume>
      <fpage>
       593
      </fpage>
      <lpage>
       602
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xit1WqsLnK
      </pub-id>
      <pub-id pub-id-type="pmid">
       35999292
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41568-022-00497-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR54">
     <label>
      54.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bian
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Deciphering human macrophage development at single-cell resolution
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2020
      </year>
      <volume>
       582
      </volume>
      <fpage>
       571
      </fpage>
      <lpage>
       576
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2020Natur.582..571B
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXpvVantL0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32499656
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41586-020-2316-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR55">
     <label>
      55.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         He
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A human fetal lung cell atlas uncovers proximal-distal gradients of differentiation and key regulators of epithelial fates
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2022
      </year>
      <volume>
       185
      </volume>
      <fpage>
       4841
      </fpage>
      <lpage>
       4860.e25
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XjtVOqsbzE
      </pub-id>
      <pub-id pub-id-type="pmid">
       36493756
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2022.11.005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR56">
     <label>
      56.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mulder
        </surname>
        <given-names>
         K
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
      </article-title>
      <source>
       Immunity
      </source>
      <year>
       2021
      </year>
      <volume>
       54
      </volume>
      <fpage>
       1883
      </fpage>
      <lpage>
       1900.e5
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhs1yiu7zK
      </pub-id>
      <pub-id pub-id-type="pmid">
       34331874
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.immuni.2021.07.007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR57">
     <label>
      57.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sharma
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2020
      </year>
      <volume>
       183
      </volume>
      <fpage>
       377
      </fpage>
      <lpage>
       394.e21
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhvFGqsLzO
      </pub-id>
      <pub-id pub-id-type="pmid">
       32976798
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2020.08.040
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR58">
     <label>
      58.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chauvin
        </surname>
        <given-names>
         J-M
        </given-names>
       </name>
       <name>
        <surname>
         Zarour
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       TIGIT in cancer immunotherapy
      </article-title>
      <source>
       J. Immunother. Cancer
      </source>
      <year>
       2020
      </year>
      <volume>
       8
      </volume>
      <pub-id pub-id-type="pmid">
       32900861
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7477968
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1136/jitc-2020-000957
      </pub-id>
      <elocation-id>
       e000957
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR59">
     <label>
      59.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Acharya
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Sabatos-Peyton
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         AC
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Tim-3 finds its place in the cancer immunotherapy landscape
      </article-title>
      <source>
       J. Immunother. Cancer
      </source>
      <year>
       2020
      </year>
      <volume>
       8
      </volume>
      <pub-id pub-id-type="pmid">
       32601081
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7326247
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1136/jitc-2020-000911
      </pub-id>
      <elocation-id>
       e000911
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR60">
     <label>
      60.
     </label>
     <mixed-citation publication-type="other">
      GlaxoSmithKline.
      <italic>
       A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
      </italic>
      .
      <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT04446351">
       https://clinicaltrials.gov/study/NCT04446351
      </ext-link>
      (2023).
     </mixed-citation>
    </ref>
    <ref id="CR61">
     <label>
      61.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <name>
        <surname>
         Fan
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <name>
        <surname>
         Yang
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <name>
        <surname>
         Gu
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Iron metabolism and its contribution to cancer (review)
      </article-title>
      <source>
       Int. J. Oncol.
      </source>
      <year>
       2019
      </year>
      <volume>
       54
      </volume>
      <fpage>
       1143
      </fpage>
      <lpage>
       1154
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtlWkur%2FN
      </pub-id>
      <pub-id pub-id-type="pmid">
       30968149
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR62">
     <label>
      62.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Viitala
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Immunotherapeutic blockade of macrophage clever-1 reactivates the CD8+ T-cell response against immunosuppressive tumors
      </article-title>
      <source>
       Clin. Cancer Res.
      </source>
      <year>
       2019
      </year>
      <volume>
       25
      </volume>
      <fpage>
       3289
      </fpage>
      <lpage>
       3303
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsFSktLrF
      </pub-id>
      <pub-id pub-id-type="pmid">
       30755440
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1158/1078-0432.CCR-18-3016
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR63">
     <label>
      63.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Park
        </surname>
        <given-names>
         S-Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Stabilin-1 mediates phosphatidylserine-dependent clearance of cell corpses in alternatively activated macrophages
      </article-title>
      <source>
       J. Cell Sci.
      </source>
      <year>
       2009
      </year>
      <volume>
       122
      </volume>
      <fpage>
       3365
      </fpage>
      <lpage>
       3373
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXhtlSitL3F
      </pub-id>
      <pub-id pub-id-type="pmid">
       19726632
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1242/jcs.049569
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR64">
     <label>
      64.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2019
      </year>
      <volume>
       20
      </volume>
      <pub-id pub-id-type="pmid">
       30902100
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6431044
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-019-1662-y
      </pub-id>
      <elocation-id>
       63
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR65">
     <label>
      65.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wolf
        </surname>
        <given-names>
         FA
        </given-names>
       </name>
       <name>
        <surname>
         Angerer
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <name>
        <surname>
         Theis
        </surname>
        <given-names>
         FJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       SCANPY: large-scale single-cell gene expression data analysis
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2018
      </year>
      <volume>
       19
      </volume>
      <pub-id pub-id-type="pmid">
       29409532
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5802054
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-017-1382-0
      </pub-id>
      <elocation-id>
       15
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR66">
     <label>
      66.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wolock
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <name>
        <surname>
         Lopez
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Klein
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Scrublet: computational identification of cell doublets in single-cell transcriptomic data
      </article-title>
      <source>
       Cell Syst.
      </source>
      <year>
       2019
      </year>
      <volume>
       8
      </volume>
      <fpage>
       281
      </fpage>
      <lpage>
       291.e9
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXosVyhtbw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       30954476
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6625319
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cels.2018.11.005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR67">
     <label>
      67.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Korsunsky
        </surname>
        <given-names>
         I
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Fast, sensitive and accurate integration of single-cell data with harmony
      </article-title>
      <source>
       Nat. Methods
      </source>
      <year>
       2019
      </year>
      <volume>
       16
      </volume>
      <fpage>
       1289
      </fpage>
      <lpage>
       1296
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXitFOqsr7N
      </pub-id>
      <pub-id pub-id-type="pmid">
       31740819
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6884693
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41592-019-0619-0
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR68">
     <label>
      68.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tran
        </surname>
        <given-names>
         HTN
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A benchmark of batch-effect correction methods for single-cell RNA sequencing data
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2020
      </year>
      <volume>
       21
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXkvVWlt7g%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       31948481
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6964114
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-019-1850-9
      </pub-id>
      <elocation-id>
       12
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR69">
     <label>
      69.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Traag
        </surname>
        <given-names>
         VA
        </given-names>
       </name>
       <name>
        <surname>
         Waltman
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         van Eck
        </surname>
        <given-names>
         NJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       From Louvain to Leiden: guaranteeing well-connected communities
      </article-title>
      <source>
       Sci. Rep.
      </source>
      <year>
       2019
      </year>
      <volume>
       9
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2019NatSR...9.5233T
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BB3cbosVGisQ%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       30914743
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6435756
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41598-019-41695-z
      </pub-id>
      <elocation-id>
       5233
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR70">
     <label>
      70.
     </label>
     <mixed-citation publication-type="other">
      McInnes, L., Healy, J. &amp; Melville, J. UMAP: uniform manifold approximation and projection for dimension reduction. Preprint at
      <ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1802.03426">
       https://arxiv.org/abs/1802.03426
      </ext-link>
      (2018).
     </mixed-citation>
    </ref>
    <ref id="CR71">
     <label>
      71.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mann
        </surname>
        <given-names>
         HB
        </given-names>
       </name>
       <name>
        <surname>
         Whitney
        </surname>
        <given-names>
         DR
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       On a test of whether one of two random variables is stochastically larger than the other
      </article-title>
      <source>
       Ann. Math. Stat.
      </source>
      <year>
       1947
      </year>
      <volume>
       18
      </volume>
      <fpage>
       50
      </fpage>
      <lpage>
       60
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       22058
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1214/aoms/1177730491
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR72">
     <label>
      72.
     </label>
     <mixed-citation publication-type="other">
      Haynes, W. Bonferroni correction. In
      <italic>
       Encyclopedia of Systems Biology
      </italic>
      (eds Dubitzky, W. et al.) 154–154 (Springer New York, 2013).
     </mixed-citation>
    </ref>
    <ref id="CR73">
     <label>
      73.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Love
        </surname>
        <given-names>
         MI
        </given-names>
       </name>
       <name>
        <surname>
         Huber
        </surname>
        <given-names>
         W
        </given-names>
       </name>
       <name>
        <surname>
         Anders
        </surname>
        <given-names>
         S
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2014
      </year>
      <volume>
       15
      </volume>
      <pub-id pub-id-type="pmid">
       25516281
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4302049
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-014-0550-8
      </pub-id>
      <elocation-id>
       550
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR74">
     <label>
      74.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Yu
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         L-G
        </given-names>
       </name>
       <name>
        <surname>
         Han
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <name>
        <surname>
         He
        </surname>
        <given-names>
         Q-Y
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       clusterProfiler: an R package for comparing biological themes among gene clusters
      </article-title>
      <source>
       Omics J. Integr. Biol.
      </source>
      <year>
       2012
      </year>
      <volume>
       16
      </volume>
      <fpage>
       284
      </fpage>
      <lpage>
       287
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC38XmsFarsLw%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1089/omi.2011.0118
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR75">
     <label>
      75.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus RNA-seq
      </article-title>
      <source>
       Nat. Methods
      </source>
      <year>
       2020
      </year>
      <volume>
       17
      </volume>
      <fpage>
       793
      </fpage>
      <lpage>
       798
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVKktL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       32719530
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7437817
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41592-020-0905-x
      </pub-id>
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec31">
     <title>
      Urefu wa taarifa
     </title>
     <p id="Par68">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_48700_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_48700_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_48700_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_48700_MOESM4_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_48700_MOESM5_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Dataset 1
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec32">
     <title>
      Urefu wa taarifa
     </title>
     <p id="Par69">
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_48700_MOESM6_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source Data file
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title/>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-48700-8">
     https://doi.org/10.1038/s41467-024-48700-8
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
